

Skin and Tissue Substitutes



INDEPENDENT CARE HEALTH PLAN

Effective Date: 01/01/2024

Revision Date: Click or tap to enter a date.

Review Date: Click or tap to enter a date.

Policy Number: WI.PA-1208

Line of Business: Medicare

Medicare Advantage Medical Coverage Policy

Table of Contents

[Related Medical/Pharmacy Coverage Policies](#)

[Related Documents](#)

[Description](#)

[Coverage Determination](#)

[Coverage Limitations](#)

[Coding Information](#)

[References](#)

[Appendix](#)

[Change Summary](#)

Disclaimer

The Coverage Summaries are reviewed by the iCare Medicare Utilization Management Committee. Policies in this document may be modified by a member's coverage document. Clinical policy is not intended to preempt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. References to CPT® codes or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee of claims payment. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise, without permission from iCare.

Related Medicare Advantage Medical/Pharmacy Coverage Policies

None

Related Documents

Please refer to [CMS website](#) for the most current applicable National Coverage Determination (NCD)/ Local Coverage Determination (LCD)/Local Coverage Article (LCA)/CMS Online Manual System/ Transmittals.

Type	Title	ID Number	Jurisdiction Medicare Administrative	Applicable States/Territories
------	-------	-----------	--	----------------------------------

			Contractors (MACs)	
NCD	Porcine Skin and Gradient Pressure Dressings	270.5		
LCD LCA	Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	L39624 A59434	J5 - Wisconsin Physicians Service Insurance Corporation J8 - Wisconsin Physicians Service Insurance Corporation	IA, KS, MO, NE IN, MI
LCD LCA	Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	L39116 A58865	JE - Noridian Healthcare Solutions, LLC	CA, HI, NV, American Samoa, Guam, Northern Mariana Islands
LCD LCA	Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	L39118 A58867	JF - Noridian Healthcare Solutions, LLC	AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY
LCD LCA	Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound	L39128 A58883	JJ - Palmetto GBA (Part A/B MAC) JM - Palmetto GBA (Part A/B MAC)	AL, GA, TN NC, SC, VA, WV
LCD LCA	Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities Billing and Coding: Skin Substitutes Grafts/Cellular Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers	L36690 A56696	J15 - CGS Administrators, LLC (Part A/B MAC)	KY, OH
LCD LCA	Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers	L35041 A54117	JH - Novitas Solutions, Inc. (Part A/B MAC)	AR, CO, NM, OK, TX, LA, MS DE, D.C., MD, NJ, PA

	Billing and Coding: Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers		JL - Novitas Solutions, Inc. (Part A/B MAC)	
LCD LCA	<p>Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers</p> <p>Billing and Coding: Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers</p>	<p>L36377</p> <p>A57680</p>	JN - First Coast Service Options, Inc. (Part A/B MAC)	FL, PR, U.S. VI

Description

Bioengineered skin and soft tissue substitutes are acellular (no biological component) or cellular (contain living cells) matrices. Acellular dermal matrices (ADM) or extracellular matrices (ECM) have had all cellular material removed during the manufacturing process and contain a matrix or scaffold composed of materials such as collagen, elastin, fibronectin and hyaluronic acid. These products vary in a number of ways including source (eg, biological tissue, synthetic materials or a combination), additives (eg, antibiotics, surfactants), hydration (eg, freeze dried, wet) and required preparation (eg, multiple rinses, rehydration).

Cellular matrices contain living cells such as fibroblasts and keratinocytes within a matrix which are derived from either human tissue (autologous or allogeneic) or animal tissue (xenographic), synthetic materials or a composite of these materials.

Manufacturing processes of bioengineered skin and tissue substitutes vary by company, but generally involve seeding selected cells onto a matrix, where they receive proteins and growth factors necessary for them to multiply and develop into the desired tissue. The tissue may be used for a variety of conditions and procedures including breast reconstruction, healing of lower extremity ulcers (eg, diabetic and/or venous ulcers), ocular defects, plantar fasciitis, surgical wounds and treatment of severe burns.

Coverage Determination

iCare follows the CMS requirements that only allows coverage and payment for services that are reasonable and necessary for the diagnosis and treatment of illness or injury or to improve the functioning of a malformed body member except as specifically allowed by Medicare.

In interpreting or supplementing the criteria above and in order to determine medical necessity consistently, iCare may consider the following criteria:

Skin and tissue substitutes will be considered medically reasonable and necessary when the following requirements are met:

Skin / Tissue Substitute	Indication(s) / Criteria	Associated HCPCS Code(s)
<p><u>AlloDerm Select RTM</u> Processed from human cadaver skin with the cells responsible for immune response and graft rejection removed. The remainder is a matrix or framework of natural biological components, ready to enable the body to mount its own tissue regeneration process.</p>	<ul style="list-style-type: none"> For use in association with a covered, medically necessary breast reconstruction procedure <p>(For information regarding coverage determination/limitations for breast reconstruction, please refer to Breast Reconstruction Medicare Advantage Medical Coverage Policy)</p>	<p>Q4116</p>
<p><u>Apligraf</u> Much like human skin as it has two primary layers; the epidermal (outer) layer consists of live human keratinocytes, while the dermal (inner) layer contains living fibroblasts. Also referred to as human skin equivalent.</p>	<ul style="list-style-type: none"> Use with standard therapeutic compression for the treatment of noninfected partial- and full-thickness skin ulcers due to venous insufficiency of greater than 4 weeks duration and have not adequately responded to standard wound therapy; OR Individual with type 1 or type 2 diabetes mellitus, who have full-thickness, neuropathic diabetic foot ulcers of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure 	<p>Q4101</p>
<p><u>Biobrane/Biobrane-L</u> Constructed using collagen (porcine type 1) that is incorporated with both silicone and nylon and mechanically bonded to a flexible knitted nylon fabric.</p>	<ul style="list-style-type: none"> Full-thickness (third-degree) burns; OR Partial-thickness (second-degree) burns 	<p>Q4100</p>
<p><u>Cortiva and Cortiva 1 mm Allograft Dermis</u> Non-crosslinked acellular dermal matrix.</p>	<ul style="list-style-type: none"> For use in association with a covered, medically necessary breast reconstruction procedure <p>(For information regarding coverage determination/limitations for breast</p>	<p>Q4100, C1763</p>

	reconstruction , please refer to Breast Reconstruction Medicare Advantage Medical Coverage Policy)	
<u>DermACELL</u> Acellular human dermis.	<ul style="list-style-type: none"> For use in association with a covered, medically necessary breast reconstruction procedure <p>(For information regarding coverage determination/limitations for breast reconstruction, please refer to Breast Reconstruction Medicare Advantage Medical Coverage Policy)</p>	Q4122
<u>Dermagraft</u> Manufactured from human fibroblast cells derived from newborn foreskin tissue. The fibroblasts are cultured on a bioabsorbable polyglactin mesh. Proteins and growth factors are secreted during the culture period and generate a three dimensional (3D) human dermis.	<ul style="list-style-type: none"> Full-thickness, neuropathic diabetic ulcers of the plantar surface of the foot, of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure; AND Used in conjunction with standard wound therapy 	Q4106
<u>Epifix</u> Biologic human amniotic membrane.	<ul style="list-style-type: none"> Full-thickness diabetic foot ulcers greater than 4 weeks duration that extend through the dermis, but without bone, capsule, muscle or tendon exposure; AND Used in conjunction with standard wound therapy 	Q4186
<u>FlexHD</u> Human allograft skin minimally processed to remove epidermal and dermal cells and preserve the ECM of the dermis.	<ul style="list-style-type: none"> For use in association with a covered, medically necessary breast reconstruction procedure (excluding implant-based breast reconstruction) <p>(For information regarding coverage determination/limitations for breast reconstruction, please refer to Breast Reconstruction Medicare Advantage Medical Coverage Policy)</p>	Q4128
<u>Grafix Core/Grafix Prime</u> ECM containing growth factors.	<ul style="list-style-type: none"> Treatment of partial- and full-thickness neuropathic diabetic foot ulcers that are greater than 4 weeks in duration, with no bone, capsule or tendon exposed, 	Q4132, Q4133

	when used in conjunction with standard wound therapy	
<p><u>GraftJacket Regenerative Tissue Matrix</u> Derived from cadaveric skin, which undergoes a process that removes the epidermis and dermal cells. The human dermal tissue is preserved. Over time, the body's natural repair process converts the matrix into living tissue.</p>	<ul style="list-style-type: none"> • Full-thickness diabetic foot ulcers greater than 4 weeks duration that extend through the dermis, but without bone, capsule, muscle or tendon exposure; AND • Used in conjunction with standard wound therapy 	Q4107
<p><u>Integra Bilayer Matrix Wound Dressing</u> Comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan and a semipermeable polysiloxane (silicone layer). The collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth.</p>	<ul style="list-style-type: none"> • Treatment of chronic venous or diabetic partial- and full-thickness ulcers, of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure; OR • Partial-thickness (second-degree) burns 	Q4104
<p><u>Integra Dermal Regeneration Template/Omnigraft</u> Bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer.</p>	<ul style="list-style-type: none"> • Postexcisional treatment of life-threatening, full-thickness or deep partial-thickness thermal injuries where sufficient autograft is not available at the time of excision or not desirable due to the physiological condition of the individual; OR • Repair of scar contractures when other therapies have failed or when donor sites for repair are not sufficient or desirable due to the physiological condition of the individual; OR • Treatment of partial- and full-thickness neuropathic diabetic foot ulcers that are greater than 4 weeks in duration, with no bone, capsule or tendon exposed, when used in conjunction with standard wound therapy 	Q4105
<p><u>Integra Meshed Bilayer Wound Matrix</u> Porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan. The collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth. The meshed bilayer matrix allows drainage of wound</p>	<ul style="list-style-type: none"> • Treatment of chronic venous or diabetic partial- and full-thickness ulcers, of greater than 4 weeks duration that have not adequately responded to standard wound therapy, where there is no bone, capsule, muscle or tendon exposure; OR 	Q4104, C9363

<p>exudate and provides a flexible adherent covering for the wound surface.</p>	<ul style="list-style-type: none"> • Partial-thickness (second-degree) burns 	
<p><u>Oasis Ultra Tri-Layer Matrix</u> and <u>Oasis Wound Matrix</u> A naturally derived, ECM created from the submucosal layer of porcine small intestine.</p>	<ul style="list-style-type: none"> • For treatment of difficult to heal chronic venous or diabetic partial- and full-thickness ulcers of the lower extremity that have failed standard wound therapy of at least 4 weeks duration 	<p>Q4124, Q4102</p>
<p><u>Transcyte</u> Combines a synthetic epidermis with a bioengineered human dermal layer that contains fibronectin growth factors and collagen</p>	<ul style="list-style-type: none"> • For use as a temporary wound covering for surgically excised full-thickness and deep partial-thickness thermal burn wounds in an individual who requires such a covering prior to autograft placement; OR • Treatment of mid-dermal to indeterminate depth burn wounds that typically require debridement and that may be expected to heal without autografting 	<p>Q4182</p>

The use of the criteria in this Medicare Advantage Medical Coverage Policy provides clinical benefits highly likely to outweigh any clinical harms. Services that do not meet the criteria above are not medically necessary and thus do not provide a clinical benefit. Medically unnecessary services carry risks of adverse outcomes and may interfere with the pursuit of other treatments which have demonstrated efficacy.

Coverage Limitations

[US Government Publishing Office. Electronic code of federal regulations: part 411 – 42 CFR § 411.15 - Particular services excluded from coverage](#)

The following will not be considered medically reasonable and necessary for **ANY** other indication or when the above criteria are not met including, but may not be limited to:

- AlloDerm Select RTM; **OR**
- Apligraf; **OR**
- Biobrane/Biobrane-L; **OR**
- Cortiva and Cortiva 1 mm Allograft Dermis; **OR**
- DermACELL; **OR**
- Dermagraft; **OR**
- Epifix; **OR**
- FlexHD; **OR**
- Grafix Core/Grafix Prime; **OR**

- GraftJacket Regenerative Tissue Matrix; **OR**
- Integra Bilayer Matrix Wound Dressing; **OR**
- Integra Dermal Regeneration Template/Omnigraft (Integra DRT); **OR**
- Integra Meshed Bilayer Wound Matrix; **OR**
- Oasis Ultra-Tri-Layer Matrix; **OR**
- Oasis Wound Matrix; **OR**
- Transcyte

A review of the current medical literature shows that the evidence is insufficient and there remains an absence of randomized, blinded clinical studies examining benefit and long-term clinical outcomes establishing the value of this service in clinical management.

The following, or any other skin or tissue substitutes, not addressed in the Coverage Determination section will not be considered medically reasonable and necessary for **ANY** indication. A review of the current medical literature shows that there is no evidence to determine that these services are standard medical treatments. There is an absence of randomized, blinded clinical studies examining benefit and long-term clinical outcomes establishing the value of these services in clinical management.

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>AC5 Advanced Wound System</u> Lyophilized peptide in sterile water for injection. Biocompatible and resorbable peptides that self-assemble into a nanofiber network which resembles the construct of the extracellular matrix.</p>	<ul style="list-style-type: none"> • Topical dressing for the management of wounds including: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grfts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Venous ulcers 	A2020
<p><u>ACTISHIELD, ACTISHIELD CF</u> Allografts derived from dehydrated human amniotic tissue.</p>	<ul style="list-style-type: none"> • Homologous use to cover and protect tissue 	Q4100
<p><u>ActiveBarrier, ActiveMatrix, CryoMatrix</u> Placental connective tissue matrix.</p>	<ul style="list-style-type: none"> • Surgical use to supplement or replace damaged or inadequate connective tissue 	Q4100
<p><u>Affinity</u></p>	<ul style="list-style-type: none"> • Onlay graft for: 	Q4159

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Minimally processed amniotic fluid membrane allograft.	<ul style="list-style-type: none"> ○ Acute and chronic wounds including neuropathic ulcers, pressure ulcers and venous stasis ulcers ○ Burns ○ Postsurgical wounds ○ Posttraumatic wounds 	
<u>Allogen Liquid</u> Human liquid amnion.	<ul style="list-style-type: none"> ● Burns ● Chronic, nonhealing wounds 	Q4212
<u>AlloMax</u> A sterile regenerative human collagen matrix.	<ul style="list-style-type: none"> ● Soft tissue repair including: <ul style="list-style-type: none"> ○ Breast reconstruction ○ Chest wall defect ○ Hernia repair 	Q4100
<u>Allopatch HD</u> Acellular human dermis derived from human allograft skin that is processed to preserve and maintain the natural biomechanical, biochemical and matrix properties of the dermal graft.	<ul style="list-style-type: none"> ● Provision of ECM scaffold for tendon augmentation 	Q4128
<u>AlloSkin, AlloSkin AC, AlloSkin RT</u> Allograft derived from epidermal and dermal cadaveric tissue.	<ul style="list-style-type: none"> ● Acute and chronic wound therapy 	Q4115, Q4141, Q4123
<u>Allowrap DS or dry</u> Double-sided epithelial layer human amniotic membrane.	<ul style="list-style-type: none"> ● Onlay and/or wrapping tissue applications following surgical repair 	Q4150
<u>AltiPly, AMNIOREPAIR</u> Lyophilized placental membrane allografts.	<ul style="list-style-type: none"> ● Acute and chronic wound therapy 	Q4235
<u>Amnio wound</u> Lyophilized human amniotic membrane allograft comprised of an epithelial layer and two fibrous connective tissue layers specifically processed to be used for the repair and replacement of lost or damaged dermal tissue.	<ul style="list-style-type: none"> ● Intended for the following conditions: <ul style="list-style-type: none"> ○ Adhesion barrier ○ Burn wounds ○ Diabetic ulcers ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pre- and post-surgical wounds ○ Pressure injuries ○ Scar tissue ○ Venous stasis ulcers 	Q4181

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Amnio-Maxx</u> Dual layered, dehydrated, amniotic tissue membrane graft.</p> <p><u>Amnio-Maxx Lite</u> Single layer, dehydrated, amniotic tissue membrane graft.</p>	<ul style="list-style-type: none"> • Chronic wound covering for: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ Soft tissue defects ○ Venous stasis ulcers 	Q4239
<p><u>AmnioAMP-MP</u> Decellularized dehydrated human amniotic membrane (DDHAM) which is derived from the placental amnion.</p>	<ul style="list-style-type: none"> • Partial- or full-thickness skin wounds such as: <ul style="list-style-type: none"> ○ Burns ○ Diabetic ulcers ○ Pressure ulcers ○ Venous ulcers • Repair of skin over any wound including those with exposed bone, muscle or tendon 	Q4250
<p><u>Amnioarmor</u> Dehydrated human amniotic membrane allograft derived from the submucosa of placental tissue.</p>	<ul style="list-style-type: none"> • Acute and chronic wound therapy 	Q4188
<p><u>Amnioband or Guardian – Membrane, Particulate</u> Human tissue allografts made of donated placental membranes.</p>	<ul style="list-style-type: none"> • Soft tissue defects • Surgical sites • Ulcers • Wounds 	Q4151, Q4168
<p><u>AmnioBind</u> Dehydrated, full thickness placental membrane (PM) allograft consisting of amnion, chorion, and the associated intermediate (spongy) layer (IL).</p>	<ul style="list-style-type: none"> • Acute and chronic wound therapy 	Q4225
<p><u>AmnioCord, EpiCord</u> Dehydrated, nonviable cellular umbilical cord allograft.</p>	<ul style="list-style-type: none"> • Connective tissue matrix to replace or supplement damaged or inadequate integumental tissue • Surgical wrap or barrier 	Q4100
<p><u>AmnioCore</u> Dual layer amniotic tissue allograft.</p>	<ul style="list-style-type: none"> • Acute and chronic wound therapy 	Q4227
<p><u>AmnioCyte</u> Minimally manipulated human tissue allograft derived from the extracellular matrix of the amniotic membrane.</p>	<ul style="list-style-type: none"> • Replace or supplement damaged or inadequate tissue 	Q4242

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>AmnioFill</u> Cellular tissue matrix allograft that contains multiple ECM proteins, growth factors, cytokines, and other specialty proteins.</p>	<ul style="list-style-type: none"> • Modulate inflammation in the surgical site • Reduce scar tissue formation • Replace or supplement damaged or inadequate integumental tissue for acute and chronic wounds 	Q4100
<p><u>AmnioFix</u> Human amniotic membrane comprises the innermost layer of the placenta and lines the amniotic cavity.</p>	<ul style="list-style-type: none"> • Modulate inflammation in the surgical site • Reduce scar tissue formation • Surgical wrap or barrier 	Q4100
<p><u>AmnioFLEX, ASG Barrier, ASG Fluid</u> Human tissue, chorion free allograft, comprised of minimally manipulated amniotic membrane derived from placental tissue.</p>	<ul style="list-style-type: none"> • Aid in the healing and repair of wounds • Construct a natural scaffold for new tissue growth 	Q4100
<p><u>AmnioGraft</u> Minimally manipulated, cryopreserved amniotic membrane.</p>	<ul style="list-style-type: none"> • Any indication other than ocular use (eg, diabetic ulcer) <p>(For information regarding coverage determination/ limitations for ocular indications, please refer to Ocular Surface Disease Diagnosis and Treatments Medical Coverage Policy)</p>	Q4100, V2790
<p><u>AmnioHeal Plus</u> Amniotic membrane graft</p>	<ul style="list-style-type: none"> • Chronic wound covering for: <ul style="list-style-type: none"> ○ Burns ○ Diabetic ulcers ○ Pressure ulcers ○ Venous stasis ulcers 	Q4100
<p><u>AmnioMatrix</u> Cryopreserved (frozen) complex of amniotic tissue, liquid human allograft.</p>	<ul style="list-style-type: none"> • Anti-inflammatory wound dressing • Hollow regions of bone • Soft tissue injuries 	Q4139
<p><u>Amnion Bio, AxoBioMembrane</u> Human amnion allograft.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds • Partial- or full-thickness skin wounds 	Q4211

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Amniopro, Amniogen-45, Amniogen-200, BioRenew, BioSkin, WoundEx</u> Human ECM placental tissue allografts.</p>	<ul style="list-style-type: none"> • Wounds and soft tissue defects 	Q4163
<p><u>Amniopro Flow, Amniogen-a, Amniogen-c, BioRenew Flo, BioSkin Flo, WoundEx Flo</u> Human ECM placental tissue injectable allografts.</p>	<ul style="list-style-type: none"> • Wounds and soft tissue defects 	Q4162
<p><u>Amniotext</u> Minimally manipulated, amniotic membrane derived human tissue allograft.</p>	<ul style="list-style-type: none"> • Provides a barrier and support function to aid in healing of defect 	Q4245
<p><u>Amniotext patch</u> Minimally manipulated amniotic membrane derived human tissue allograft.</p>	<ul style="list-style-type: none"> • Management of chronic wounds including: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Venous ulcers 	Q4247
<p><u>AmnioWrap2</u> Amniotic/chorionic tissue allograft.</p>	<ul style="list-style-type: none"> • Management of wounds including: <ul style="list-style-type: none"> ○ Acute and chronic wounds ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Venous ulcers 	Q4221
<p><u>Amniply</u> Collagenous membrane derived from the submucosa of the placenta.</p>	<ul style="list-style-type: none"> • Chronic wound covering for: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Pressure ulcers ○ Venous leg ulcers 	Q4249
<p><u>Apis</u> Biodegradable and absorbable gelatin, a porcine collagen derivative, is the primary material. The two other materials are Manuka honey and hydroxyapatite.</p>	<ul style="list-style-type: none"> • Management of wounds including: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, healing by secondary intention) ○ Venous ulcers 	A2010

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Architect, Architect PX, Architect FX ECM</u> Stabilized collagen matrix.</p>	<ul style="list-style-type: none"> • Partial- or full-thickness skin wounds such as: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Second-degree burns ○ Venous leg ulcers 	<p>Q4147</p>
<p><u>Artacent AC</u> Human amnion/chorion membrane graft.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds such as: <ul style="list-style-type: none"> ○ Burns ○ Diabetic ulcers ○ Pressure ulcers ○ Venous stasis ulcers ○ Wounds that are refractory to more conservative care 	<p>Q4189, Q4190</p>
<p><u>Artacent Cord</u> Umbilical cord allograft.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds such as: <ul style="list-style-type: none"> ○ Burns ○ Diabetic ulcers ○ Venous stasis ulcers ○ Wounds that are refractory to more conservative care 	<p>Q4216</p>
<p><u>Artacent – Flex, Wound</u> Amniotic tissue graft with an epithelial layer of native membrane facing out on both sides.</p>	<ul style="list-style-type: none"> • Surgical barrier for these types of surgeries: <ul style="list-style-type: none"> ○ Extremity ○ Orthopedic ○ Plastics ○ Spinal ○ Urological ○ Vascular 	<p>Q4169</p>
<p><u>ArthroFlex</u> Decellularized dermis patch.</p>	<ul style="list-style-type: none"> • Achilles tendon repair and shoulder reconstruction 	<p>Q4125</p>
<p><u>Ascent</u></p>	<ul style="list-style-type: none"> • Burns • Chronic, nonhealing wounds 	<p>Q4213</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Dehydrated cell and protein concentrate (dCPC) injectable derived from human amniotic fluid.		
<u>Avance Nerve Graft</u> Processed, decellularized nerve allograft.	<ul style="list-style-type: none"> • Alternative to nerve conduits for nerve repair procedures 	64912, 64913
<u>Axograft</u> Dual layer amniotic membrane.	<ul style="list-style-type: none"> • Promote bone healing, spinal fusion and wound treatment in spinal arthrodesis procedures 	Q4100
<u>AxoGuard – Nerve Connector, Nerve Protector</u> Porcine submucosa ECM.	<ul style="list-style-type: none"> • Coaptation aid for close approximation and reinforcement of severed nerve ends • Isolate nerve tissue during the healing process 	C1763
<u>Axolotl Ambient, Axolotl Cryo</u> Human amniotic flowable allografts.	<ul style="list-style-type: none"> • Soft tissue injuries 	Q4215
<u>Axolotl DualGraft, Axolotl Graft</u> Human amniotic allograft, decellularized, dehydrated placental membrane.	<ul style="list-style-type: none"> • Wound barrier • Nerve wrap 	Q4210
<u>Barrera SL, Barrera DL</u> Dehydrated human amniotic membrane allograft.	<ul style="list-style-type: none"> • Barrier or cover for wounds including surgically created wounds 	Q4281
<u>BellaCell HD</u> Human acellular dehydrated dermis regenerative tissue matrix.	<ul style="list-style-type: none"> • Abdominal wall and hiatal hernia repair • Breast reconstruction • Burns • Skin ulcers 	Q4220
<u>Bio-ConneKt</u> Conformable and porous wound dressing made of reconstituted collagen derived from equine tendon.	<ul style="list-style-type: none"> • Management of moderately to heavily exuding wounds including: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds 	Q4161

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Venous ulcers 	
<p><u>Biodesign – Dural Graft, Duraplasty Graft, ENT Repair Graft, Otologic Repair Graft</u> Nonporous, absorbable multi-layer sheet of extracellular collagen matrix derived from porcine SIS.</p>	<ul style="list-style-type: none"> ● Repair of soft tissue defects including: <ul style="list-style-type: none"> ○ Dura mater ○ Sinonasal ○ Tympanic membrane 	C1763
<p><u>Biodesign – Enterocutaneous Fistula Plug and Fistula Plug</u> Cone-shaped plug made of connective tissue from porcine small intestine submucosa (SIS).</p>	<ul style="list-style-type: none"> ● The plug is absorbed into the body in 6 – 8 weeks ● The plug is inserted into the fistula and sutured into place, where it is intended to provide a framework for the body's own cells and blood vessels to infiltrate and promote healing 	C1763, 46707
<p><u>Biodesign – Hernia, Hiatal Hernia, Incision Graft</u> Multilayered sheet of extracellular collagen matrix derived from porcine small intestinal submucosa (SIS).</p>	<ul style="list-style-type: none"> ● Abdominal wall reconstruction and hernia repair 	C1763
<p><u>Biodesign Nipple Reconstruction Cylinder</u> Rolled cylinder of extracellular collagen matrix derived from porcine small intestinal submucosa (SIS).</p>	<ul style="list-style-type: none"> ● Support weakened soft tissue during nipple reconstruction 	C1763
<p><u>Biodesign Tissue Graft – 1 layer, 4 layer</u> Dried single or multilayer porcine SIS sheet.</p>	<ul style="list-style-type: none"> ● Reinforcement of soft tissue 	C1763
<p><u>BioDExCel (AmnioExCel)</u></p>	<ul style="list-style-type: none"> ● Scaffold for tissue repair and regeneration 	Q4137

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Amniotic extracellular membrane is a sterile, resorbable, noncross-linked tissue allograft derived from the human amnion.		
BioDFactor, BioDFence, BioDDryFlex ECM and flowable tissue allografts derived from human placental tissues.	<ul style="list-style-type: none"> • Localized areas of inflammation • Supports soft tissue regeneration • Tissue voids and defects 	Q4140, Q4138
BioFix, BioFix Plus, BioFix Flow Amniotic allografts are derived from human placental tissue.	<ul style="list-style-type: none"> • Wound covering for: <ul style="list-style-type: none"> ○ Surgical sites ○ Tissue defects ○ Tissue voids 	Q4100
Biovance Dehydrated, decellularized human amniotic membrane.	<ul style="list-style-type: none"> • Treatment or replacement of damaged or lost soft tissue 	Q4154
Biovance Tri-layer, Biovance 3L Triple-layer decellularized, dehydrated human amniotic membrane.	<ul style="list-style-type: none"> • Cover or protect, from the surrounding environment, in wound, surgical repair and reconstruction procedures 	Q4283
BioWound, BioWound Plus, BioWound XPlus, WoundFix, WoundFix Plus, WoundFix XPlus Human amnion-based membranes.	<ul style="list-style-type: none"> • Repair of acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Burns ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	Q4217

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> • Repair of skin over any wound including those with exposed bone, capsule, muscle or tendon 	
<p><u>Celera Dual Membrane, Celera Dual Layer</u> Amniotic and/or chorionic allograft derived from placental tissue.</p>	<ul style="list-style-type: none"> • Wound covering or barrier membrane 	Q4259
<p><u>Cellesta</u> Minimally manipulated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Burns • Chronic wound repair • Urologic and gynecological surgeries 	Q4184
<p><u>Cellesta Cord</u> Umbilical cord allograft product.</p>	<ul style="list-style-type: none"> • Acute and chronic wound therapy • Surgical wounds 	Q4214
<p><u>Cellesta Flowable Amnion</u> Minimally manipulated, chorion-free human amniotic membrane.</p>	<ul style="list-style-type: none"> • Application in difficult to access wound sites, deep dermal wounds, irregularly shaped crevassing and tunneling wounds 	Q4185
<p><u>Cocoon Membrane</u> Human amnionic membrane allograft.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds • Partial- or full-thickness skin wounds 	Q4264
<p><u>Cogenex Amniotic Membrane</u> Minimally manipulated, amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Burns • Chronic, nonhealing wounds • Urologic and gynecological surgeries 	Q4229
<p><u>Cogenex Flowable Amnion</u> Minimally manipulated, amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Application in difficult to access wound sites, deep dermal wounds, irregularly shaped crevassing and tunneling wounds 	Q4230
<p><u>Coll-e-derm</u> Allograft derived from human dermal tissue.</p>	<ul style="list-style-type: none"> • Regenerative support to wounds and burns 	Q4193
<p><u>Complete FT</u> Resorbable full-thickness amnion/chorion allograft.</p>	<ul style="list-style-type: none"> • Wound covering or barrier membrane, over acute and chronic wounds 	Q4271
<p><u>Complete SL</u> Resorbable single layer amniotic allograft.</p>	<ul style="list-style-type: none"> • Wound covering or barrier membrane, over acute and chronic wounds 	Q4270
<p><u>CopiOs Pericardium Membrane</u></p>	<ul style="list-style-type: none"> • Guided tissue and bone regeneration in oral surgery procedures 	C1763

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Bovine pericardium-based, noncross-linked collagen matrix.		
<u>CoreCyte</u> Wharton's jelly allograft.	<ul style="list-style-type: none"> • Aid in the healing and repair of wounds 	Q4240
<u>CoreText, ProText</u> Wharton's jelly allograft.	<ul style="list-style-type: none"> • Cartilage tears • Muscle tears • Soft tissue defects • Wounds 	Q4246
<u>CorMatrix ECM</u> Acellular biomaterial (porcine small intestine submucosa processed to remove cells) the remaining ECM is composed of structural proteins such as collagen, elastin, etc.	<ul style="list-style-type: none"> • Support cardiac repairs and gradually replace tissue as it is remodeled, leaving no foreign material behind 	C1763
<u>Corplex</u> Human umbilical cord allograft composed of the epithelial layer and the Wharton's jelly.	<ul style="list-style-type: none"> • Acute and chronic wound therapy 	Q4232
<u>Corplex P</u> Wharton's jelly allograft.	<ul style="list-style-type: none"> • Wound covering for connective tissue voids 	Q4231
<u>Cryo-Cord</u> Minimally manipulated umbilical cord allograft.	<ul style="list-style-type: none"> • Chronic, nonhealing wounds 	Q4237
<u>Cygnus Dual</u> Amniotic tissue matrix.	<ul style="list-style-type: none"> • Barrier or cover for wounds 	Q4282
<u>Cygnus Matrix</u> Amniotic tissue matrix.	<ul style="list-style-type: none"> • Burn care • Dermatology • Foot and ankle surgery • Oral surgery • Reconstructive surgery • Spine and neurosurgery • Urology • Wound care 	Q4199
<u>Cygnus – Max, Solo</u> Amniotic tissue matrix.	<ul style="list-style-type: none"> • Burn care • Dermatology • Foot and ankle surgery • Oral surgery • Reconstructive surgery • Spine and neurosurgery • Urology • Wound care 	Q4170

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Cymetra Micronized AlloDerm Tissue Matrix</u> Micronized particulate form of AlloDerm, delivered by injection containing collagens, elastin, proteins and proteoglycans.</p>	<ul style="list-style-type: none"> • Correction of soft tissue defects requiring minimally invasive techniques 	<p>Q4112</p>
<p><u>Cytal – Burn Matrix, Micro Matrix and Wound Matrix</u> (formerly MatriStem Wound Matrix and Multilayer Wound Matrix)</p> <p>Noncross-linked urinary bladder matrix (UBM) that maintains an epithelial basement membrane and numerous collagens.</p>	<ul style="list-style-type: none"> • Management of topical wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	<p>Q4166</p>
<p><u>Derm-Maxx</u> Freeze-dried decellularized dermal matrix allograft.</p>	<ul style="list-style-type: none"> • Repair or replacement of damaged or inadequate integumental tissue 	<p>Q4238</p>
<p><u>Derma-Gide</u> Comprised of a porcine derived, porous, purified collagen matrix.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ Full- and partial-thickness wounds 	<p>Q4203</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	
<p><u>Dermabind SL</u> Dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	Q4284
<p><u>Dermacyte</u> Amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Diabetic foot ulcers ● Partial-thickness wounds ● Venous stasis ulcers 	Q4248
<p><u>DermaMatrix</u> Allograft derived from donated human skin.</p>	<ul style="list-style-type: none"> ● Repair, replacement or reinforcement of soft tissue for grafting purposes 	Q4100
<p><u>DermaPure</u></p>	<ul style="list-style-type: none"> ● Acute and chronic wounds such as: 	Q4152

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Derived from split-thickness grafts harvested from human cadaver tissue donors.	<ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Venous stasis ulcers ○ Wounds that are refractory to more conservative care 	
<p><u>DermaSpan ACD</u> ADM derived from allograft human skin.</p>	<ul style="list-style-type: none"> ● Covering, protection, reinforcement or supplemental support of tendon ● Homologous uses of human integument ● Repair or replacement of damaged or inadequate integumental tissue 	Q4126
<p><u>Dermavest, Plurivest</u> Amnion/chorion, umbilical cord and placental disk tissue preserved with attachment proteins, growth factors and cytokines.</p>	<ul style="list-style-type: none"> ● Skin replacement or supplement for damaged or inadequate integumental tissue such as surgical sites, ulcers or wounds 	Q4153
<p><u>DermMatrix (formerly InteXen) Porcine Dermal Matrix</u> Pyrogen free, porcine dermis.</p>	<ul style="list-style-type: none"> ● Implantation to reinforce soft tissues in gastroenterological, gynecological and urological anatomy ● Treatment of hernias where the connective tissue has ruptured 	Q4100
<p><u>Dual Layer Impax Membrane</u> Dehydrated dual layered human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Wound covering or barrier membrane 	Q4262
<p><u>DuraGen</u> Onlay graft comprised of a porous, purified collagen matrix.</p>	<ul style="list-style-type: none"> ● Absorbable implant for the repair of dura mater 	Q4100
<p><u>E-Z Derm</u> Porcine derived xenograft in which the collagen has been chemically cross-linked with aldehyde (a chemical compound).</p>	<ul style="list-style-type: none"> ● Alternative to allografts in the treatment of burn wounds, especially for partial-thickness skin losses ● Protection for meshed autografts ● Temporary coverage prior to autograft 	Q4136
<p><u>EndoForm Dermal Template, Myriad</u> ECM derived from ovine forestomach.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	A6021, A6022

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Inverse</u> Dehydrated human amniotic membrane.</p>	<ul style="list-style-type: none"> ● Wound covering or barrier membrane, over acute and chronic wounds, including dermal ulcers or defects 	Q4258
<p><u>Epicel</u> Skin cells are grown or cultured from a postage stamp sized sample of the individual’s own healthy skin.</p>	<ul style="list-style-type: none"> ● Replace the epidermis on a severely burned individual 	Q4100
<p><u>Epicord, Epifix</u> Biologic human amniotic membrane.</p>	<ul style="list-style-type: none"> ● Burns ● Plastic surgery ● Wound care 	Q4145, Q4187
<p><u>Epieffect</u> Human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds 	Q4278
<p><u>Esano A</u> Single-layer, decellularized, dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds 	Q4272
<p><u>Esano AAA</u> Tri-layer, decellularized, dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds 	Q4273

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Esano AC</u> Dual-layer, decellularized, dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Barrier or cover for acute and chronic wounds 	Q4274
<p><u>Esano ACA</u> Tri-layer, decellularized, dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Barrier or cover for acute and chronic wounds 	Q4275
<p><u>Excellagen</u> Pharmaceutically formulated fibrillar Type I bovine collagen gel.</p>	<ul style="list-style-type: none"> • Applied immediately following wound debridement • Purported to promote: <ul style="list-style-type: none"> ○ Cellular adhesion ○ Chemotaxis ○ Migration and proliferation to stimulate granulation tissue formation 	Q4149
<p><u>FloGraft</u> Cryopreserved, injectable, liquid amniotic fluid derived allograft.</p>	<ul style="list-style-type: none"> • Soft tissue repair 	Q4100
<p><u>Floweramnioflo</u> Premixed, ambient temperature placental tissue matrix allograft.</p>	<ul style="list-style-type: none"> • Replace or supplement damaged or integumental tissue 	Q4177
<p><u>Floweramniopatch</u> Dehydrated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Wound covering 	Q4178
<p><u>Flowerderm</u> Acellular dermal allograft ECM composed of proteoglycans, hyaluronic acid, collagen, fibronectin and elastin.</p>	<ul style="list-style-type: none"> • Reinforcement of tendons and supplemental support • Wound covering 	Q4179
<p><u>Fluid Flow, Fluid GF</u> Human amniotic flowable allograft.</p>	<ul style="list-style-type: none"> • Acute and chronic wound therapy • Soft tissue injuries 	Q4206
<p><u>Fortify Flowable</u> Extracellular matrix (ECM) derived from porcine small intestinal submucosa.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds 	A4100, Q4100

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Fortiva Porcine Dermis</u> Noncross-linked porcine dermis, designed to act as a scaffold that allows for neovascularization and reincorporation with the individual’s own tissue.</p>	<ul style="list-style-type: none"> ● Soft tissue repair procedures such as hernia repair 	Q4100
<p><u>GalaFLEX, GalaFLEX 3D and GalaFLEX 3DR</u> Bioresorbable surgical scaffold made of monofilament fibers of the biopolymer, poly-4-hydroxybutarate (P4HB).</p>	<ul style="list-style-type: none"> ● Reinforcing scaffold in soft tissue repair procedures such as: <ul style="list-style-type: none"> ○ General soft tissue reconstruction ○ Plastic and reconstructive surgery 	A4100, Q4100
<p><u>GammaGraft</u> Irradiated human skin allograft acquired from cadaveric donors.</p>	<ul style="list-style-type: none"> ● Temporary graft for treating: <ul style="list-style-type: none"> ○ Burns ○ Chronic wounds ○ Full-thickness wounds ○ Partial-thickness wounds 	Q4111
<p><u>Genesis Amniotic Membrane</u> Dehydrated, collagenous human tissue allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wound therapy ● Soft tissue injuries 	Q4198

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Gentrix Surgical Matrix</u> (formerly MatriStem Surgical Matrix) Composed of a porcine derived ECM, also known as UBM and supplied in multilayer sheet configurations.</p>	<ul style="list-style-type: none"> • Reinforcement of soft tissue within gastroenterological, plastic, reconstructive or urological surgery including, but may not be limited to, the following procedures: <ul style="list-style-type: none"> ○ Colon and rectal prolapse repair ○ Esophageal repair ○ Hernia and body wall repair ○ Tissue repair 	<p>C1763, C1781</p>
<p><u>GraftJacket Xpress</u> Injectable allograft treatment that is mixed with sterile saline.</p>	<ul style="list-style-type: none"> • Facilitate the rapid formation of granulation tissue and reduce infection risk 	<p>Q4113</p>
<p><u>Helicoll</u> Helicoll is an ADM derived from bovine Type-1 collagen.</p>	<ul style="list-style-type: none"> • Full- and partial-thickness wounds • Second-degree burns • Skin donor sites • Skin ulcers • Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) 	<p>Q4164</p>
<p><u>hMatrix</u> Acellular, dermal scaffold processed from donated human skin.</p>	<ul style="list-style-type: none"> • Replace damaged or inadequate integumental tissue such as: <ul style="list-style-type: none"> ○ Abdominal wall repair ○ Breast reconstruction ○ Wound covering 	<p>Q4134</p>
<p><u>Human Health Factor 10 Amniotic Patch (hhf10-p)</u> Single-layer amniotic allograft derived from full-term human birth tissue, specifically the immunoprivileged amnion layer.</p>	<ul style="list-style-type: none"> • Wound covering or barrier membrane 	<p>Q4224</p>
<p><u>Hyalomatrix</u></p>	<ul style="list-style-type: none"> • Full-thickness wounds and burns 	<p>Q4117</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p>Bioresorbable, dermal substitute made of HYAFF, a long-acting derivative of hyaluronic acid providing a microenvironment.</p>	<ul style="list-style-type: none"> • Provides a wound preparation to support the implantation of autologous skin grafts 	
<p><u>InnovaBurn, InnovaMatrix XL</u> Decellularized extracellular matrix (ECM) derived from porcine placental tissue.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	<p>A2022</p>
<p><u>InnovaMatrix AC</u> Decellularized extracellular matrix (ECM) topical wound covering derived from porcine placental tissue.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds 	<p>A2001</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>InnovaMatrix FS</u> Decellularized extracellular matrix (ECM) topical wound covering derived from porcine placental tissue.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds 	<p>A2013</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Venous ulcers 	
<p><u>InnovaMatrix PD</u> Decellularized extracellular matrix (ECM) derived from porcine placental tissue.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	A2023
<p><u>Integra Flowable Wound Matrix</u> Comprised of granulated cross- linked bovine tendon collagen and glycosaminoglycan; hydrated with saline.</p>	<ul style="list-style-type: none"> ● Difficult to access wound sites, as well as tunneled wounds. 	Q4114
<p><u>Integra HuMend ADM</u> Human dermal allograft that has been decellularized while preserving the noncellular natural biologic components and structure of the dermal matrix.</p>	<ul style="list-style-type: none"> ● Reinforcing scaffold in soft tissue repair procedures such as: <ul style="list-style-type: none"> ○ Abdominal wall reconstruction ○ Breast reconstruction ● Tendon protection 	Q4100

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Integra Matrix Wound Dressing</u> Biodegradable, porous matrix of cross-linked bovine tendon and glycosaminoglycan.</p>	<ul style="list-style-type: none"> • Scaffold for cellular invasion and capillary growth 	<p>Q4108</p>
<p><u>Interfyl – Flowable, Particulate</u> Decellularized, connective ECM derived from human placental tissue.</p>	<ul style="list-style-type: none"> • Correct defects and fill voids and in soft tissue, providing mechanical and structural support to facilitate the tissue repair process 	<p>Q4171</p>
<p><u>Keramatrix</u> Absorbable matrix made from a combination of keratin technology that dissolves into wounds.</p>	<ul style="list-style-type: none"> • Full- and partial-thickness wounds with low to high exudate 	<p>Q4165</p>
<p><u>Kerecis Omega3</u> Acellular intact fish skin that contains proteins, lipids (including omega3) and other skin elements and bioactive lipid content.</p>	<ul style="list-style-type: none"> • Reconstruction of: <ul style="list-style-type: none"> ○ Breast ○ Burns ○ Chronic wounds ○ Dura mater ○ Hernia repair ○ Oral wounds 	<p>Q4158</p>
<p><u>Kerecis Omega3 MariGen Shield</u> Acellular intact fish skin that contains proteins, lipids (including omega3) and other skin elements and bioactive lipid content.</p>	<ul style="list-style-type: none"> • Management of wounds including: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) 	<p>A2019</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Venous ulcers 	
<p><u>Keroxx</u> Flowable matrix made from a combination of keratin technology that dissolves into wounds.</p>	<ul style="list-style-type: none"> ● Chronic wounds such as: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ Donor sites/grafts ○ Pressure ulcers 	Q4202
<p><u>Leneva</u> Allograft adipose extracellular matrix (ECM).</p>	<ul style="list-style-type: none"> ● Soft tissue reconstruction 	Q4100
<p><u>MatriDerm</u> Acellular dermal substitute composed of bovine collagen and elastin.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	Q4100
<p><u>Matrion</u> Matrix scaffold derived from an intact decellularized placental membrane comprising both amniotic and chorionic layers.</p>	<ul style="list-style-type: none"> ● Chronic wounds 	Q4201
<p><u>MatriStem MicroMatrix</u> Noncross-linked basement membrane compromised of urinary bladder matrix (UBM) and various collagens.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	Q4118

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Matrix HD</u> Acellular human dermis allograft retains the three-dimensional intertwined multidirectional fibers and mechanical properties of the native tissue architecture.</p>	<ul style="list-style-type: none"> ● Protect, reinforce or cover soft tissue and provide a scaffold to support regenerative processes 	Q4128
<p><u>Mediskin</u> Frozen irradiated porcine xenograft with a dermal and epidermal layer.</p>	<ul style="list-style-type: none"> ● Meshed autograft protection ● Partial-thickness skin ulcerations and abrasions ● Temporary covering for full-thickness skin loss ● Toxic epidermal necrolysis (TEN) 	Q4135
<p><u>Membrane Graft, Membrane Wrap</u> Human amniotic allograft.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Burns 	Q4205

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Ulcers caused by mixed vascular etiologies ○ Venous ulcers 	
<p><u>MemoDerm</u> ADM derived from human allograft skin tissue.</p>	<ul style="list-style-type: none"> ● Repairs (eg, rotator cuff) and wounds (eg, chronic diabetic ulcer) 	Q4126
<p><u>Microlyte Matrix</u> Synthetic absorbent polyvinyl alcohol hydrogel sheet with a polymeric surface coating containing ionic and metallic silver.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Diabetic ulcers ○ First and second-degree burns ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, lacerations, skin tears) ○ Venous ulcers 	A2005
<p><u>Miro3D</u> Decellularized extracellular matrix (ECM) derived from porcine liver tissue.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	A2025

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Miroderm, Miromesh</u> Noncross-linked acellular wound matrix derived from porcine liver and is processed and stored in a phosphate buffered aqueous solution.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) 	<p>Q4175</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Mirrugen Advanced Wound Matrix</u> Biocompatible and resorbable borate glass fibers and particulate.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	A2002
<p><u>MLG-Complete</u> Full thickness amnion-chorion derived allograft.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	Q4256

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>MyOwn Skin</u> Autologous, homologous human skin product.</p>	<ul style="list-style-type: none"> ● Chronic wounds ● Postsurgical wounds 	Q4226
<p><u>NeoMatriX Wound Matrix</u> Acellular axolotl dermal extracellular matrix.</p>	<ul style="list-style-type: none"> ● Management of wounds including: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) 	A2021

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	
<p><u>Neopatch</u> Terminally sterilized, dehydrated human placental membrane tissue comprised of both amnion and chorion.</p>	<ul style="list-style-type: none"> ● External wound covering for dermal ulcerations including: <ul style="list-style-type: none"> ○ Chronic venous ulcers ○ Diabetic ulcers 	Q4176
<p><u>Neostim DL</u> Double layer dehydrated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	Q4267
<p><u>Neostim Membrane</u> Single layer dehydrated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	Q4266

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	
<p><u>Neostim TL</u> Triple layer dehydrated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	<p>Q4265</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Neox 100; OR</u> Cryopreserved human amniotic membrane and umbilical cord.</p> <p><u>Clarix 100</u> Cryopreserved human amniotic membrane, umbilical cord and additional proteins.</p>	<ul style="list-style-type: none"> • Surgical wrap or barrier, quick-peel matrix • Wound covering for dermal ulcers and defects, quick-peel matrix 	Q4156
<p><u>Neox Cord 1K; OR</u> Cryopreserved human amniotic membrane and umbilical cord.</p> <p><u>Clarix Cord 1K</u> Cryopreserved human amniotic membrane, umbilical cord and additional proteins.</p>	<ul style="list-style-type: none"> • Surgical wrap or barrier, 1 mm thick form • Wound covering for dermal ulcers and defects, 1 mm thick form 	Q4148
<p><u>Neox Flo or Clarix Flo</u> Particulate products of the above-mentioned matrices.</p>	<ul style="list-style-type: none"> • Replace or supplement damaged or inadequate integumental tissue 	Q4155
<p><u>NeuraGen Nerve Guide, NeuraWrap Nerve Protector</u> Bovine derived collagen conduit.</p>	<ul style="list-style-type: none"> • Repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity 	C1763
<p><u>NeuroMend Nerve Wrap</u> Resorbable, semipermeable, type I collagen nerve wrap.</p>	<ul style="list-style-type: none"> • Peripheral nerve repair 	C9361
<p><u>Novachor</u> Chorion layer of the placental membranes.</p>	<ul style="list-style-type: none"> • Onlay graft for: <ul style="list-style-type: none"> ○ Acute and chronic wounds including neuropathic ulcers, pressure ulcers and venous stasis ulcers ○ Burns ○ Postsurgical wounds ○ Posttraumatic wounds 	Q4194
<p><u>Novafix</u> Dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers 	Q4208

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Novafix DL</u> Dehydrated human amnion chorion membrane allograft.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) 	<p>Q4254</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>NovoSorb Matrix</u> Acellular, synthetic dermal matrix of biodegradable polyurethane foam bonded with a polyurethane adhesive layer.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	A2006
<p><u>NuCel</u> Allograft derived from human amnion and amniotic fluid.</p>	<ul style="list-style-type: none"> ● Provides an environment for tissue growth, repair and healing 	Q4100
<p><u>NuDyn, SurFactor</u> Acellular, flowable human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds ● Burns ● Soft tissue injuries ● Surgical wounds 	Q4233
<p><u>NuDYN DL, NuDYN DL MESH</u> Human amnion/chorion membrane allografts.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers 	Q4285

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>NuDYN SL, NuDYN SLW</u> Human amnion membrane allografts.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) 	<p>Q4286</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>NuShield</u> Allograft derived from amniotic and chorionic membranes.</p>	<ul style="list-style-type: none"> ● Assist in healing of soft tissue injuries ● Barrier protection of dura, nerves and tendons ● Burns ● Wound covering 	Q4160
<p><u>Oasis Burn Matrix</u> Naturally derived, ECM created from the submucosal layer of porcine small intestine.</p>	<ul style="list-style-type: none"> ● Acellular scaffold that accommodates remodeling of host tissue 	Q4103
<p><u>ologen Collagen Matrix</u> Biodegradable porcine-derived collagen matrix.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Oral wounds/sores ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds ○ Trauma wounds (eg, second-degree burns) 	Q4100

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Omeza Collagen Matrix</u> Hydrolyzed fish collagen infused with cod liver oil.</p>	<ul style="list-style-type: none"> ○ Venous ulcers ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	<p>A2014</p>
<p><u>Orion</u> Dual-layer, dehydrated human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds 	<p>Q4276</p>
<p><u>OrthoFlo</u> Allograft derived from amniotic fluid.</p>	<ul style="list-style-type: none"> ● For use in joints to: <ul style="list-style-type: none"> ○ Modulate inflammation ○ Protect and cushion ○ Provide lubrication for enhanced mobility 	<p>Q4100</p>
<p><u>OviTex</u></p>	<ul style="list-style-type: none"> ● Reinforce and/or repair soft tissue where weakness exists 	<p>Q4100</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Bio scaffold composed of ovine (sheep) derived ECM and polyglycolic acid (PGA).	<ul style="list-style-type: none"> • Repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material 	
<p><u>PalinGen – Flow, SportFlow, XPlus or ProMatrX</u></p> <p>Human amniotic tissue allograft comprised of amnion and amniotic fluid containing growth factors, cytokines and ECM proteins naturally found in amniotic tissue.</p>	<ul style="list-style-type: none"> • Aid in healing and repair of wounds • Wound covering and support for native tissue 	Q4173, Q4174
<p><u>Permacol</u></p> <p>A porcine dermal collagen implant.</p>	<ul style="list-style-type: none"> • Patch to reinforce soft tissue where weakness occurs • Surgical repair of damaged or ruptured soft tissue 	C9364
<p><u>PermeaDerm B</u></p> <p>Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.</p>	<ul style="list-style-type: none"> • Partial-thickness burns • Skin donor sites 	A2016
<p><u>PermeaDerm CW</u></p> <p>Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grfts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) 	A2018

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	
<p><u>PermeaDerm Glove</u> Monofilament nylon knitted fabric bonded to a thin slitted silicone membrane. The nylon side of this dressing is coated with a mixture of porcine gelatin and a pure fraction of aloe vera.</p>	<ul style="list-style-type: none"> ● Debrided partial-thickness hand burns 	A2017
<p><u>Phoenix Wound Matrix</u> Bioabsorbable, conformable, non-woven, fibrous, three-dimensional matrix. Composed of poly(lactide-co-caprolactone) and polyglycolic acid.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Full- and partial-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	A2015
<p><u>PolyCyte</u> Minimally manipulated human tissue allograft derived from the Wharton's jelly of the umbilical cord.</p>	<ul style="list-style-type: none"> ● Replace or supplement damaged or inadequate tissue 	Q4241

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>PRECLUDE Vessel Guard</u> Three-layer construction with two outer layers consisting of a tight expanded polytetrafluoroethylene (ePTFE) microstructure.</p>	<ul style="list-style-type: none"> • Cover for vessels following anterior vertebral surgery, providing a plane of dissection 	<p>Q4100</p>
<p><u>PriMatrix</u> ADM derived from fetal bovine skin.</p>	<ul style="list-style-type: none"> • Scaffold capable of being integrated, remodeled and eventually replaced by functional host tissue 	<p>Q4110</p>
<p><u>Procenta</u> Acellular, sterile human placental derived allograft.</p>	<ul style="list-style-type: none"> • Chronic wound covering for: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Venous stasis ulcers 	<p>Q4244</p>
<p><u>ProgenaMatrix</u> Human keratin matrix derived from human hair.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ First and second-degree burns ○ Partial- and full-thickness wounds ○ Surgical wounds (eg, donor sites/grafts) ○ Trauma wounds (eg, abrasions, lacerations, skin tears) ○ Venous ulcers 	<p>Q4222</p>
<p><u>ProLayer</u> Human acellular dermal matrix.</p>	<ul style="list-style-type: none"> • Reinforcement of soft tissue including: <ul style="list-style-type: none"> ○ Breast reconstruction 	<p>Q4100</p>
<p><u>Promogran Matrix</u> Freeze-dried composite prepared from bone collagen and oxidized regenerated cellulose.</p>	<ul style="list-style-type: none"> • Bind and protect the functionality of growth factors, such as platelet-derived growth factors (PDGF) in hostile proteolytic environments 	<p>Q4100</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>PuraPly, PuraPly AM, PuraPly XT</u> Purified Type 1 native collagen matrix creates a durable biocompatible scaffold.</p>	<ul style="list-style-type: none"> • Barrier against a wide array of microorganisms • Inhibit formation of biofilm on the wound surface 	<p>Q4195, Q4196, Q4197</p>
<p><u>Puros Dermis</u> A natural biological matrix.</p>	<ul style="list-style-type: none"> • Periodontal/peri-implant soft tissue management • Soft tissue enhancement 	<p>Q4100</p>
<p><u>REGUaRD</u> Hydrated acellular human dermal allograft matrix.</p>	<ul style="list-style-type: none"> • Burns • Chronic, nonhealing wounds 	<p>Q4255</p>
<p><u>Relese</u> Dehydrated human amniotic membrane obtained from donated placental tissue.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds including dermal ulcers and other defects 	<p>Q4257</p>
<p><u>Repliform</u> Acellular human dermis.</p>	<ul style="list-style-type: none"> • Pelvic floor repair 	<p>Q4100</p>
<p><u>Repriza</u> <i>Pre hydrated, ready to use, ADM prepared from human skin allograft.</i></p>	<ul style="list-style-type: none"> • Reconstructive surgery wherever an ADM may be used including, but may not be limited to: <ul style="list-style-type: none"> ○ Abdominal wall reconstruction ○ Augmentation of soft tissue irregularities ○ Breast reconstruction 	<p>Q4143</p>
<p><u>Resolve Matrix</u> Non-crosslinked acellular wound dressing derived from porcine peritoneum membrane.</p>	<ul style="list-style-type: none"> • Management of topical wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers 	<p>A2024</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	
<p><u>Restorigin</u> Amnion umbilical cord tissue.</p>	<ul style="list-style-type: none"> ● Burns ● Chronic, nonhealing wounds 	<p>Q4191, Q4192</p>
<p><u>Restrata</u> Resorbable nanofiber wound matrix.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds 	<p>A2007</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Venous ulcers 	
<p><u>Revita</u> Dehydrated, sterile human amniotic membrane and chorionic membrane.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds, including defects and dermal ulcers ● Wound covering or barrier membrane 	Q4180
<p><u>Revitalon</u> Composed of native human amnion and chorion in addition to collagen and growth factors.</p>	<ul style="list-style-type: none"> ● Damaged membranes ● Dressing for burns ● Full-thickness wounds 	Q4157
<p><u>RX Flow, RX Membrane</u> Placental connective tissue matrix.</p>	<ul style="list-style-type: none"> ● Surgical use to supplement or replace damaged or inadequate connective tissue 	Q4100
<p><u>Signature APatch</u> Amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Repair of acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Burns ○ Diabetic foot ulcers ○ Pressure ulcers ○ Surgical wounds ○ Venous leg ulcers ● Wounds with exposed bone, muscle and/or tendon 	Q4260
<p><u>SimpliDerm</u> Human acellular dermal matrix.</p>	<ul style="list-style-type: none"> ● Replacement of damaged or inadequate integumental tissue ● Soft tissue defects 	Q4100
<p><u>SkinTE</u> Autologous, homologous, full –thickness skin product composed of viable skin cells and an organized extracellular matrix.</p>	<ul style="list-style-type: none"> ● Burns ● Chronic wounds ● Homologous uses of human integument 	Q4200
<p><u>StrataGraft</u> Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat.</p>	<ul style="list-style-type: none"> ● Adults with thermal burns containing intact dermal elements (eg, deep partial-thickness burns) 	Q4100

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Strattice Reconstructive Tissue Matrix</u> Derived from porcine dermis, which undergoes nondamaging processing that removes cells and reduces the key component in the xenogeneic rejection response.</p>	<ul style="list-style-type: none"> • Surgical repair of damaged or ruptured soft tissue • Surgically implanted patch to reinforce where weakness exists 	Q4130
<p><u>Stravix</u> Cryopreserved human placental tissue composed of umbilical amnion and Wharton’s jelly.</p>	<ul style="list-style-type: none"> • Wrap to aid in surgical procedures and wound repair 	Q4100
<p><u>Supra SDRM</u> Biodegradable matrix wound dressing fabricated from a tri-polymer of polylactide, trimethylene carbonate, ε-caprolactone and polyvinyl alcohol.</p>	<ul style="list-style-type: none"> • Acute and chronic wounds such as: <ul style="list-style-type: none"> ○ Burns ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	A2011
<p><u>Suprathel</u> Bioresorbable dermal covering, composed entirely of synthetic materials, including a tripolymer of polylactide, s-caprolactone and trimethylene carbonate.</p>	<ul style="list-style-type: none"> • Dermal wounds such as: <ul style="list-style-type: none"> ○ Abrasions ○ Burns ○ Split-thickness skin graft donor sites 	A2012
<p><u>SureDerm</u></p>	<ul style="list-style-type: none"> • Burns 	Q4220

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
Human acellular dermal matrix.	<ul style="list-style-type: none"> • Periodontal soft tissue management • Skin ulcers 	
<p><u>SurgiCORD</u> Umbilical tissue membrane allograft.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pressure injuries ○ Venous stasis ulcers 	Q4218
<p><u>Surgigraft</u> Human amnion-only regenerative extracellular tissue matrix.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Adhesion barrier ○ Burn wounds ○ Diabetic ulcers ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pre- and post-surgical wounds ○ Pressure injuries ○ Scar tissue ○ Venous stasis ulcers 	Q4183
<p><u>SurgiGRAFT-DUAL</u> Minimally processed bilayer allograft.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Neuropathic ulcers ○ Post-traumatic wounds ○ Pressure injuries 	Q4219
<p><u>SurgiMend Collagen Matrix</u> Acellular tissue matrix of either fetal or neonatal bovine origin.</p>	<ul style="list-style-type: none"> • Breast reconstruction • Reinforcement for weak or damaged soft tissues 	C9358, C9360
<p><u>SurGraft</u> Dehydrated amniotic membrane sheet.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Burns ○ Diabetic ulcers ○ Full- and partial-thickness wounds 	Q4209

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Pressure wounds ○ Surgical wounds ○ Venous ulcers 	
<p><u>SurGraft FT</u> Full-thickness amnion/chorion tissue allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	<p>Q4268</p>
<p><u>SurGraft TL</u> Triple layer amniotic tissue allograft.</p>	<ul style="list-style-type: none"> ● Repair of acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds 	<p>Q4263</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Venous ulcers 	
<p><u>SurGraft XT</u> Dual layer amniotic tissue allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	<p>Q4269</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>Symphony</u> Extracellular matrix (ECM) derived from ovine forestomach tissue.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds ○ Venous ulcers 	<p>A2009</p>
<p><u>TAG</u> Triple layer amniotic allograft derived from placental tissue.</p>	<ul style="list-style-type: none"> • Wound covering or barrier membrane, over acute and chronic wounds 	<p>Q4261</p>
<p><u>Talymed</u> Advanced matrix composed of shortened fibers isolated from microalgae.</p>	<ul style="list-style-type: none"> • Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Abrasions ○ Chronic vascular ulcers ○ Dehisced surgical wounds ○ Diabetic ulcers 	<p>Q4127</p>

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Donor sites/grafts ○ Full- and partial-thickness wounds ○ Lacerations ○ Post-laser surgery and other bleeding surface wounds ○ Post-Mohs surgery ○ Pressure wounds ○ Second-degree burns ○ Surgical wounds ○ Traumatic wounds healing by secondary intention ○ Ulcers caused by mixed vascular etiologies ○ Venous ulcers 	
<p><u>TenSIX Acellular Dermal Matrix</u> Acellular matrix with natural histomorphology preserved.</p>	<ul style="list-style-type: none"> ● Tendon and wound coverage 	Q4146
<p><u>TheraGenesis</u> Bilayered wound matrix comprised of a porcine tendon-derived atelocollagen layer and a silicone film layer.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers 	A2008

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Surgical wounds (eg, donor sites/grafts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Venous ulcers 	
<p><u>TheraSkin</u> Biologically active cryopreserved human skin allograft with both epidermis and dermis layers; the cellular and extracellular composition provides a supply of collagen, cytokines and growth factors.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Dehisced surgical wounds ○ Diabetic foot ulcers ○ Necrotizing fasciitis ○ Pressure ulcers ○ Radiation burns ○ Venous leg ulcers ● Repair of skin over any wound including those with exposed bone, capsule, muscle or tendon 	Q4121
<p><u>TissueMend</u> Remodeled collagen matrix created from bovine skin.</p>	<ul style="list-style-type: none"> ● Reinforcement of soft tissue that is repaired using sutures or anchors during tendon repair surgery 	Q4100
<p><u>TranZgraft AC (InteguPly)</u> Acellular collagen matrix derived from human allograft skin tissue.</p>	<ul style="list-style-type: none"> ● Replace or supplement damaged or inadequate integumental tissue for acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Pressure ulcers ○ Venous leg ulcers 	Q4126
<p><u>Truskin</u> Split-thickness, cryopreserved skin allograft extracellular matrix with growth factors and endogenous living skin cells.</p>	<ul style="list-style-type: none"> ● Repair of acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Diabetic foot ulcers ○ Pressure ulcers 	Q4167

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Surgical wounds ○ Venous leg ulcers ○ Wounds with exposed bone and tendon 	
Tutomesh, Tutopatch Noncross-linked acellular collagen matrices derived from bovine pericardium.	<ul style="list-style-type: none"> ● Pericardial repair ● Soft tissue reconstruction 	C1763
Vendaje Dehydrated human amniotic membrane composed of the amnion layer.	<ul style="list-style-type: none"> ● Support and serve as a barrier for integumental tissue 	Q4252
Veritas Collagen Matrix Acellular tissue matrix derived from bovine pericardium.	<ul style="list-style-type: none"> ● Hernia repair ● Pelvic floor procedures ● Plastic and reconstructive procedures 	C9354
Viaflow, Viaflow C Flowable placental tissue matrices.	<ul style="list-style-type: none"> ● Breast reconstruction ● Tissue voids and defects 	Q4100
VIM Allograft sheet of human amnion.	<ul style="list-style-type: none"> ● Barrier for the following types of surgeries: <ul style="list-style-type: none"> ○ Ophthalmic ○ Orthopedic ● Wound covering 	Q4251
WoundPlus Membrane, E-graft Single-layer, dehydrated and devitalized human amniotic membrane allograft.	<ul style="list-style-type: none"> ● Barrier or cover for acute and chronic wounds 	Q4277
Xcell Amnio Matrix Lyophilized amniotic membrane allograft.	<ul style="list-style-type: none"> ● Acute and chronic wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Partial- and full-thickness wounds ○ Pressure ulcers 	Q4280

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
	<ul style="list-style-type: none"> ○ Surgical wounds (eg, donor sites/grfts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled/undermined wounds ○ Venous ulcers 	
<p><u>XCellerate</u> Lyophilized human amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Burns ● Chronic, nonhealing wounds 	Q4234
<p><u>XCelliStem</u> Extracellular matrix (ECM) composed of porcine collagen.</p>	<ul style="list-style-type: none"> ● Management of wounds including, but may not be limited to: <ul style="list-style-type: none"> ○ Chronic vascular ulcers ○ Diabetic ulcers ○ Draining wounds ○ Partial- and full-thickness wounds ○ Pressure ulcers ○ Surgical wounds (eg, donor sites/grfts, podiatric, post laser surgery, post-Mohs surgery, wound dehiscence) ○ Trauma wounds (eg, abrasions, lacerations, second-degree burns, skin tears) ○ Tunneled wounds ○ Undermined wounds 	A2004

Skin / Tissue Substitute	Purported Indications (Not covered for <u>ANY</u> indication)	Associated HCPCS/ CPT® Code(s)
<p><u>XCM Biologic Tissue Matrix</u> Noncross-linked 3-D matrix derived from porcine dermis.</p>	<ul style="list-style-type: none"> ○ Venous ulcers ● Reinforcement and repair of soft tissue where weakness exists, including plastic and reconstructive surgical applications ● Reinforcement of soft tissues which are repaired by suture or suture anchors 	<p>Q4142</p>
<p><u>Xelma</u> ECM protein</p>	<ul style="list-style-type: none"> ● Hard to heal wounds such as venous leg ulcers 	<p>Q4100</p>
<p><u>XenMatrix</u> Acellular noncross-linked porcine collagen scaffold with open collagen structure.</p>	<ul style="list-style-type: none"> ● Surgical repair of damaged or ruptured soft tissue, including, but may not be limited to: <ul style="list-style-type: none"> ○ Abdominal plastic and reconstructive surgery ○ Hernia repair including abdominal, diaphragmatic, femoral, incisional, inguinal, scrotal and umbilical hernias ○ Muscle flap reinforcement 	<p>C1763</p>
<p><u>XWrap Dry or Hydro Plus</u> Resorbable, chorion-free, human amnion allograft.</p>	<ul style="list-style-type: none"> ● Soft tissue defects and wounds 	<p>Q4204, Q4100</p>
<p><u>Zenapro</u> Combination of ultra-lightweight polypropylene and small intestinal submucosa (SIS).</p>	<ul style="list-style-type: none"> ● Repair of a body wall defect or hernia requiring the addition of a reinforcing or bridging material 	<p>Q4100, 49560, 49561, 49565, 49566, 49568, 49652, 49653, 49655, 49656, 49657</p>
<p><u>Zenith Amniotic Membrane</u> Dehydrated amniotic membrane allograft.</p>	<ul style="list-style-type: none"> ● Acute and chronic wound therapy ● Application in difficult to access wound sites, deep dermal wounds and irregularly shaped wounds 	<p>Q4253</p>

Coding Information

Any codes listed on this policy are for informational purposes only. Do not rely on the accuracy and inclusion of specific codes. Inclusion of a code does not guarantee coverage and/or reimbursement for a service or procedure.

CPT® Code(s)	Description	Comments
15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	
15272	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)	
15273	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)	
15274	Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	
15275	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	
15276	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)	
15277	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	

15278	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	
15777	Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (ie, breast, trunk) (List separately in addition to code for primary procedure)	
15778	Implantation of absorbable mesh or other prosthesis for delayed closure of defect(s) (ie, external genitalia, perineum, abdominal wall) due to soft tissue infection or trauma	
46707	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])	
64912	Nerve repair; with nerve allograft, each nerve, first strand (cable)	
64913	Nerve repair; with nerve allograft, each additional strand (List separately in addition to code for primary procedure)	
64999	Unlisted procedure, nervous system	
CPT® Category III Code(s)	Description	Comments
0437T	Implantation of non-biologic or synthetic implant (eg, polypropylene) for fascial reinforcement of the abdominal wall (List separately in addition to code for primary procedure)	
HCPCS Code(s)	Description	Comments
A2001	InnovaMatrix AC, per sq cm	
A2002	Mirragen Advanced Wound Matrix, per sq cm	
A2004	XCelliStem, per sq cm	
A2005	Microlyte Matrix, per sq cm	
A2006	NovoSorb SynPath dermal matrix, per sq cm	
A2007	Restrata, per sq cm	
A2008	TheraGenesis, per sq cm	
A2009	Symphony, per sq cm	
A2010	Apis, per sq cm	
A2011	Supra sdrm, per square centimeter	
A2012	Suprathel, per square centimeter	
A2013	Innovamatrix fs, per square centimeter	
A2014	Omeza collagen matrix, per 100 mg	

A2015	Phoenix wound matrix, per square centimeter	
A2016	Permeaderm b, per square centimeter	
A2017	Permeaderm glove, each	
A2018	Permeaderm c, per square centimeter	
A2019	Kerecis omega3 marigen shield, per square centimeter	
A2020	Ac5 advanced wound system (ac5)	
A2021	Neomatrix, per square centimeter	
A2022	Innovaburn or innovamatrix xl, per square centimeter	
A2023	Innovamatrix pd, 1 mg	
A2024	Resolve matrix, per square centimeter	
A2025	Miro3d, per cubic centimeter	
A4100	Skin substitute, fda cleared as a device, not otherwise specified	
A6021	Collagen dressing, sterile, size 16 sq in or less, each	
A6022	Collagen dressing, sterile, size more than 16 sq in but less than or equal to 48 sq in, each	
C1763	Connective tissue, nonhuman (includes synthetic)	
C1781	Mesh (implantable)	
C1832	Autograft suspension, including cell processing and application, and all system components	
C1849	Skin substitute, synthetic, resorbable, per sq cm	
C5271	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	
C5272	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)	
C5273	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	
C5274	Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)	
C5275	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	

C5276	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)	
C5277	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	
C5278	Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)	
C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm	
C9358	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	
C9360	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	
C9361	Collagen matrix nerve wrap (NeuroMend Collagen Nerve Wrap), per 0.5 cm length	
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm	
C9364	Porcine implant, Permacol, per sq cm	
C9399	Unclassified drugs or biologicals	
Q4100	Skin substitute, not otherwise specified	
Q4101	Apligraf, per sq cm	
Q4102	Oasis wound matrix, per sq cm	
Q4103	Oasis burn matrix, per sq cm	
Q4104	Integra bilayer matrix wound dressing (BMWD), per sq cm	
Q4105	Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix, per sq cm	
Q4106	Dermagraft, per sq cm	
Q4107	GRAFTJACKET, per sq cm	
Q4108	Integra matrix, per sq cm	
Q4110	PriMatrix, per sq cm	
Q4111	GammaGraft, per sq cm	

Q4112	Cymetra, injectable, 1 cc	
Q4113	GRAFTJACKET XPRESS, injectable, 1 cc	
Q4114	Integra flowable wound matrix, injectable, 1 cc	
Q4115	AlloSkin, per sq cm	
Q4116	AlloDerm, per sq cm	
Q4117	HYALOMATRIX, per sq cm	
Q4118	MatriStem micromatrix, 1 mg	
Q4121	TheraSkin, per sq cm	
Q4122	DermACELL, DermACELL AWM or DermACELL AWM Porous, per sq cm	
Q4123	AlloSkin RT, per sq cm	
Q4124	OASIS ultra tri-layer wound matrix, per sq cm	
Q4125	ArthroFlex, per sq cm	
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm	
Q4127	Talymed, per sq cm	
Q4128	FlexHD, AllopatchHD, or Matrix HD, per sq cm	
Q4130	Strattice TM, per sq cm	
Q4132	Grafix Core and GrafixPL Core, per sq cm	
Q4133	Grafix PRIME, GrafixPL PRIME, Stravix and StravixPL, per sq cm	
Q4134	HMatrix, per sq cm	
Q4135	Mediskin, per sq cm	
Q4136	E-Z Derm, per sq cm	
Q4137	AmnioExcel, AmnioExcel Plus or BioDExcel, per sq cm	
Q4138	BioDFence DryFlex, per sq cm	
Q4139	AmnioMatrix or BioDMatrix, injectable, 1 cc	
Q4140	BioDFence, per sq cm	
Q4141	AlloSkin AC, per sq cm	
Q4142	XCM biologic tissue matrix, per sq cm	
Q4143	Repriza, per sq cm	
Q4145	EpiFix, injectable, 1 mg	
Q4146	Tensix, per sq cm	
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	
Q4148	Neox Cord 1K, Neox Cord RT, or Clarix Cord 1K, per sq cm	
Q4149	Excellagen, 0.1 cc	
Q4150	AlloWrap DS or dry, per sq cm	
Q4151	AmnioBand or Guardian, per sq cm	
Q4152	DermaPure, per sq cm	
Q4153	Dermavest and Plurivest, per sq cm	

Q4154	Biovance, per sq cm	
Q4155	Neox Flo or Clarix Flo 1 mg	
Q4156	Neox 100 or Clarix 100, per sq cm	
Q4157	Revitalon, per sq cm	
Q4158	Kerecis Omega3, per sq cm	
Q4159	Affinity, per sq cm	
Q4160	Nushield, per sq cm	
Q4161	bio-ConneKt wound matrix, per sq cm	
Q4162	WoundEx Flow, BioSkin Flow, 0.5 cc	
Q4163	WoundEx, BioSkin, per sq cm	
Q4164	Helicoll, per sq cm	
Q4165	Keramatrix or Kerasorb, per sq cm	
Q4166	Cytal, per sq cm	
Q4167	Truskin, per sq cm	
Q4168	AmnioBand, 1 mg	
Q4169	Artacent wound, per sq cm	
Q4170	Cygnus, per sq cm	
Q4171	Interfyl, 1 mg	
Q4173	PalinGen or PalinGen XPlus, per sq cm	
Q4174	PalinGen or ProMatrX, 0.36 mg per 0.25 cc	
Q4175	Miroderm, per sq cm	
Q4176	Neopatch or therion, per square centimeter	
Q4177	FlowerAmnioFlo, 0.1 cc	
Q4178	FlowerAmnioPatch, per sq cm	
Q4179	FlowerDerm, per sq cm	
Q4180	Revita, per sq cm	
Q4181	Amnio Wound, per sq cm	
Q4182	Transcyte, per sq cm	
Q4183	Surgigraft, per sq cm	
Q4184	Cellesta or Cellesta Duo, per sq cm	
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5 cc	
Q4186	Epifix, per sq cm	
Q4187	Epicord, per sq cm	
Q4188	AmnioArmor, per sq cm	
Q4189	Artacent AC, 1 mg	
Q4190	Artacent AC, per sq cm	
Q4191	Restorigin, per sq cm	
Q4192	Restorigin, 1 cc	
Q4193	Coll-e-Derm, per sq cm	

Q4194	Novachor, per sq cm	
Q4195	PuraPly, per sq cm	
Q4196	PuraPly AM, per sq cm	
Q4197	PuraPly XT, per sq cm	
Q4198	Genesis Amniotic Membrane, per sq cm	
Q4199	Cygnus matrix, per sq cm	
Q4200	SkinTE, per sq cm	
Q4201	Matrion, per sq cm	
Q4202	Keroxx (2.5 g/cc), 1 cc	
Q4203	Derma-Gide, per sq cm	
Q4204	XWRAP, per sq cm	
Q4205	Membrane Graft or Membrane Wrap, per sq cm	
Q4206	Fluid Flow or Fluid GF, 1 cc	
Q4208	Novafix, per sq cm	
Q4209	SurGraft, per sq cm	
Q4210	Axolotl Graft or Axolotl DualGraft, per sq cm	
Q4211	Amnion Bio or AxoBioMembrane, per sq cm	
Q4212	AlloGen, per cc	
Q4213	Ascent, 0.5 mg	
Q4214	Cellesta Cord, per sq cm	
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg	
Q4216	Artacent Cord, per sq cm	
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm	
Q4218	SurgiCORD, per sq cm	
Q4219	SurgiGRAFT-DUAL, per sq cm	
Q4220	BellaCell HD or Surederm, per sq cm	
Q4221	Amnio Wrap2, per sq cm	
Q4222	ProgenaMatrix, per sq cm	
Q4224	Human health factor 10 amniotic patch (hhf10-p), per square centimeter	
Q4225	Amniobind, per square centimeter	
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm	
Q4227	AmnioCore™, per sq cm	
Q4229	Cogenex Amniotic Membrane, per sq cm	
Q4230	Cogenex Flowable Amnion, per 0.5 cc	
Q4231	Corplex P, per cc	
Q4232	Corplex, per sq cm	

Q4233	SurFactor or NuDyn, per 0.5 cc	
Q4234	XCellerate, per sq cm	
Q4235	AMNIOREPAIR or AltiPly, per sq cm	
Q4237	Cryo-Cord, per sq cm	
Q4238	Derm-Maxx, per sq cm	
Q4239	Amnio-Maxx or Amnio-Maxx Lite, per sq cm	
Q4240	CoreCyte, for topical use only, per 0.5 cc	
Q4241	PolyCyte, for topical use only, per 0.5 cc	
Q4242	AmnioCyte Plus, per 0.5 cc	
Q4244	Procenta, per 200 mg	
Q4245	AmnioText, per cc	
Q4246	CoreText or ProText, per cc	
Q4247	Amniotext patch, per sq cm	
Q4248	Dermacyte Amniotic Membrane Allograft, per sq cm	
Q4249	AMNIPLY, for topical use only, per sq cm	
Q4250	AmnioAmp-MP, per sq cm	
Q4251	Vim, per sq cm	
Q4252	Vendaje, per sq cm	
Q4253	Zenith Amniotic Membrane, per sq cm	
Q4254	Novafix DL, per sq cm	
Q4255	REGUaRD, for topical use only, per sq cm	
Q4256	Mlg-complete, per square centimeter	
Q4257	Relese, per square centimeter	
Q4258	Enverse, per square centimeter	
Q4259	Celera dual layer or celera dual membrane, per square centimeter	
Q4260	Signature apatch, per square centimeter	
Q4261	Tag, per square centimeter	
Q4262	Dual layer impax membrane, per square centimeter	
Q4263	Surgraft tl, per square centimeter	
Q4264	Cocoon membrane, per square centimeter	
Q4265	Neostim tl, per square centimeter	
Q4266	Neostim membrane, per square centimeter	
Q4267	Neostim dl, per square centimeter	
Q4268	Surgraft ft, per square centimeter	
Q4269	Surgraft xt, per square centimeter	
Q4270	Complete sl, per square centimeter	
Q4271	Complete ft, per square centimeter	
Q4272	Esano a, per square centimeter	

Q4273	Esano aaa, per square centimeter	
Q4274	Esano ac, per square centimeter	
Q4275	Esano aca, per square centimeter	
Q4276	Orion, per square centimeter	
Q4277	Woundplus membrane or e-graft, per square centimeter	
Q4278	Epieffect, per square centimeter	
Q4280	Xcell amnio matrix, per square centimeter	
Q4281	Barrera sl or barrera dl, per square centimeter	
Q4282	Cygnus dual, per square centimeter	
Q4283	Biovance tri-layer or biovance 3l, per square centimeter	
Q4284	Dermabind sl, per square centimeter	
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter	
Q4286	Nudyn sl or nudyn slw, per square centimeter	
V2790	Amniotic membrane for surgical reconstruction, per procedure	

References

1. Agency for Healthcare Research and Quality (AHRQ). Technical Brief. Skin substitutes for treating chronic wounds. <https://www.ahrq.gov>. Published February 2, 2020. Accessed December 14, 2022.
2. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (A58865). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
3. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (A58867). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
4. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (A58883). <https://www.cms.gov>. Published April 30, 2023. Accessed November 3, 2023.
5. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (A59434). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
6. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and

- Venous Leg Ulcers (A54117). <https://www.cms.gov>. Published October 1, 2015. Updated August 13, 2020. Accessed August 29, 2023.
7. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (A57680). <https://www.cms.gov>. Published October 3, 2018. Updated August 13, 2020. Accessed August 29, 2023.
 8. Centers for Medicare & Medicaid Services (CMS). Local Coverage Article (LCA). Billing and Coding: Skin Substitutes Grafts/Cellular Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (A56696). <https://www.cms.gov>. Published July 11, 2019. Updated September 1, 2022. Accessed August 29, 2023.
 9. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD). Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (L39116). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
 10. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD). Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (L39118). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
 11. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD). Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (L39128). <https://www.cms.gov>. Published April 30, 2023. Accessed November 3, 2023.
 12. Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD). Amniotic and placental-derived product injections and/or applications for musculoskeletal indications, non-wound (L39624). <https://www.cms.gov>. Published November 12, 2023. Accessed November 3, 2023.
 13. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD). Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds (L35041). <https://www.cms.gov>. Published October 1, 2015. Updated September 26, 2019. Accessed August 29, 2023.
 14. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD). Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (L36377). <https://www.cms.gov>. Published October 1, 2015. Updated September 17, 2023. Accessed August 29, 2023.
 15. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determination (LCD). Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities (L36690). <https://www.cms.gov>. Published October 10, 2016. Updated September 1, 2022. Accessed August 29, 2023.

16. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD). Porcine Skin and Gradient Pressure Dressings (270.5). <https://www.cms.gov>. Accessed August 29, 2023.
17. ECRI Institute. Clinical Evidence Assessment. AlloDerm regenerative tissue matrix (AbbVie, Inc.) for reconstructing breast tissue. <https://www.ecri.org>. Published December 18, 2018. Updated November 30, 2020. Accessed December 9, 2022.
18. ECRI Institute. Clinical Evidence Assessment. Amnioband allograft placental matrix (MTF Biologics) for treating chronic wounds. <https://www.ecri.org>. Published June 20, 2016. Updated September 23, 2020. Accessed December 6, 2022.
19. ECRI Institute. Clinical Evidence Assessment. Arthroflex acellular dermal matrix (LifeNet Health and Arthrex, Inc.) for repairing large to massive rotator cuff tears. <https://www.ecri.org>. Published October 23, 2017. Updated June 16, 2022. Accessed December 12, 2022.
20. ECRI Institute. Clinical Evidence Assessment. Biodesign sinonasal repair graft (Cook Medical, Inc.) for repairing sinus and nasal cavity defects. <https://www.ecri.org>. Published December 9, 2021. Accessed December 9, 2022.
21. ECRI Institute. Clinical Evidence Assessment. Biovance amniotic membrane allograft (Celularity, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published January 3, 2017. Updated July 24, 2020. Accessed December 9, 2022.
22. ECRI Institute. Clinical Evidence Assessment. Cortiva and Cortiva 1 mm allograft dermis (RTI Surgical, Inc.) for breast reconstruction. <https://www.ecri.org>. Published November 13, 2018. Updated November 30, 2020. Accessed December 9, 2022.
23. ECRI Institute. Clinical Evidence Assessment. Cygnus amniotic allografts (Vivex Medical, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published April 29, 2022. Accessed December 6, 2022.
24. ECRI Institute. Clinical Evidence Assessment. Dermacell advanced decellularized dermis (LifeNet Health Bio-Implants Division) for breast reconstruction. <https://www.ecri.org>. Published August 15, 2016. Updated December 2, 2020. Accessed December 9, 2022.
25. ECRI Institute. Clinical Evidence Assessment. Dermacell AWM (LifeNet Health Bio-Implants Division) for chronic wounds. <https://www.ecri.org>. Published March 8, 2018. Updated December 18, 2020. Accessed December 6, 2022.
26. ECRI Institute. Clinical Evidence Assessment. Fortify Flowable extracellular matrix (Sanara Medtech, Inc.) for treating wounds. <https://www.ecri.org>. Published October 3, 2022. Accessed December 9, 2022.
27. ECRI Institute. Clinical Evidence Assessment. GalaFlex surgical scaffold (Galatea Surgical, Inc.) for soft-tissue reinforcement in breast reconstruction Surgery. <https://www.ecri.org>. Published October 7, 2022. Accessed December 6, 2022.

28. ECRI Institute. Clinical Evidence Assessment. Grafix cellular repair matrix (Osiris Therapeutics, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published November 9, 2012. Updated July 14, 2021. Accessed December 9, 2022.
29. ECRI Institute. Clinical Evidence Assessment. Hyalomatrix tissue reconstruction matrix (Anika Therapeutics, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published June 7, 2018. Updated April 13, 2021. Accessed December 6, 2022.
30. ECRI Institute. Clinical Evidence Assessment. Integra bilayer matrix (Integra LifeSciences Corp.) for treating diabetic foot ulcers. <https://www.ecri.org>. Published April 8, 2021. Accessed December 6, 2022.
31. ECRI Institute. Clinical Evidence Assessment. Leneva allograft adipose matrix (MTF Biologics) for treating wounds. <https://www.ecri.org>. Published October 3, 2022. Accessed December 9, 2022.
32. ECRI Institute. Clinical Evidence Assessment. Matriderm (MedSkin Solutions) for managing wounds following otorhinolaryngology surgery. <https://www.ecri.org>. Published April 11, 2022. Accessed December 6, 2022.
33. ECRI Institute. Clinical Evidence Assessment. Myriad soft-tissue matrix (Aroa Biosurgery Ltd.) for treating chronic wounds. <https://www.ecri.org>. Published September 21, 2020. Accessed December 9, 2022.
34. ECRI Institute. Clinical Evidence Assessment. NEOX Flo wound matrix (AmnioX Medical, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published December 4, 2015. Updated August 27, 2021. Accessed December 9, 2022.
35. ECRI Institute. Clinical Evidence Assessment. NeuraGen 3D nerve guide (Integra LifeSciences) for repairing nerve gap injuries. <https://www.ecri.org>. Published April 28, 2022. Accessed December 9, 2022.
36. ECRI Institute. Clinical Evidence Assessment. NovoSorb biodegradable temporizing matrix (PolyNovo Ltd.) for managing wounds. <https://www.ecri.org>. Published September 1, 2019. Updated November 2, 2021. Accessed December 30, 2022.
37. ECRI Institute. Clinical Evidence Assessment. NuShield placental allograft (Organogenesis, Inc.) for treating burns. <https://www.ecri.org>. Published November 29, 2021. Accessed December 6, 2022.
38. ECRI Institute. Clinical Evidence Assessment. Omega3 wound matrix (Kerecis) for treating chronic wounds. <https://www.ecri.org>. Published June 1, 2019. Updated March 8, 2022. Accessed December 6, 2022.
39. ECRI Institute. Clinical Evidence Assessment. Overview of flowable matrices for treating chronic and acute wounds. <https://www.ecri.org>. Published September 1, 2022. Accessed December 12, 2022.

40. ECRI Institute. Clinical Evidence Assessment. Overview of selected human amniotic membranes for treating chronic wounds. <https://www.ecri.org>. Published May 1, 2022. Accessed December 9, 2022.
41. ECRI Institute. Clinical Evidence Assessment. OviTex PRS reinforced tissue matrix (TELA Bio) for breast reconstruction. <https://www.ecri.org>. Published December 13, 2021. Accessed December 9, 2022.
42. ECRI Institute. Clinical Evidence Assessment. OviTex reinforced bioscaffolds (Tela Bio, Inc.) for hernia repair. <https://www.ecri.org>. Published December 16, 2021. Accessed December 9, 2022.
43. ECRI Institute. Clinical Evidence Assessment. ProLayer acellular dermal matrix (Stryker Corp.) for breast reconstruction. <https://www.ecri.org>. Published March 4, 2022. Accessed December 9, 2022.
44. ECRI Institute. Clinical Evidence Assessment. PuraPly AM antimicrobial wound matrix (Organogenesis, Inc.) for treating chronic wounds. <https://www.ecri.org>. Published November 7, 2018. Updated April 29, 2022. Accessed December 6, 2022.
45. ECRI Institute. Clinical Evidence Assessment. Revita placental allograft (StimLabs, LLC) for treating diabetic foot ulcers. <https://www.ecri.org>. Published March 1, 2022. Accessed December 6, 2022.
46. ECRI Institute. Clinical Evidence Assessment. Skin substitutes for treating diabetic foot ulcers in patients aged 65 years or older. <https://www.ecri.org>. Published January 25, 2021. Accessed December 6, 2022.
47. ECRI Institute. Clinical Evidence Assessment. Standard-of-care practices for managing diabetic foot ulcers. <https://www.ecri.org>. Published January 28, 2020. Updated December 31, 2021. Accessed December 6, 2022.
48. ECRI Institute. Clinical Evidence Assessment. StrataGraft allogeneic cellularized scaffold (Mallinckrodt Pharmaceuticals) for treating thermal burns. <https://www.ecri.org>. Published February 6, 2022. Accessed December 6, 2022.
49. ECRI Institute. Clinical Evidence Assessment. Stravix cryopreserved placental tissue (Osiris Therapeutics, Inc.) for treating surgical wounds. <https://www.ecri.org>. Published July 8, 2021. Accessed December 6, 2022.
50. ECRI Institute. Clinical Evidence Assessment. Suprathel skin substitute (PolyMedics Innovations GmbH) for treating donor site wounds. <https://www.ecri.org>. Published February 22, 2021. Accessed December 6, 2022.
51. ECRI Institute. Clinical Evidence Assessment. SurgiMend collagen matrix (Integra LifeSciences Corp.) for breast reconstruction. <https://www.ecri.org>. Published November 14, 2019. Updated May 4, 2021. Accessed December 9, 2022.

52. ECRI Institute. Clinical Evidence Assessment. Synthetic versus biologic mesh for breast reconstructive surgery. <https://www.ecri.org>. Published October 30, 2015. Updated February 1, 2022. Accessed December 12, 2022.
53. ECRI Institute. Hotline Response. Skin substitutes for managing pilonidal disease excision wounds. <https://www.ecri.org>. Published March 31, 2020. Accessed December 6, 2022.
54. ECRI Institute. Hotline Response. Synthetic versus biologic mesh for abdominal wall reconstructive surgery. <https://www.ecri.org>. Published October 15, 2015. Updated November 13, 2019. Accessed December 12, 2022.
55. ECRI Institute. Product Brief. AmnioExcel amniotic allograft membrane (Integra LifeSciences Corp.) for treating chronic wounds. <https://www.ecri.org>. Published November 20, 2019. Accessed December 9, 2022.
56. ECRI Institute. Product Brief. AmnioFix amnion/chorion membrane allograft (MiMedx) for treating surgical wounds. <https://www.ecri.org>. Published April 14, 2015. Updated May 10, 2019. Accessed December 6, 2022.
57. ECRI Institute. Product Brief. Avance nerve graft (AxoGen, Inc.) for repairing nerve gap injuries. <https://www.ecri.org>. Published March 14, 2012. Updated January 27, 2020. Accessed December 12, 2022.
58. ECRI Institute. Product Brief. AxoGuard nerve connector (AxoGen, Inc.) for repairing peripheral nerve injuries. <https://www.ecri.org>. Published April 30, 2019. Accessed December 9, 2022.
59. ECRI Institute. Product Brief. Cortiva Allograft Dermis (RTI Surgical, Inc.) for hernia repair. <https://www.ecri.org>. Published October 1, 2018. Accessed December 12, 2022.
60. ECRI Institute. Product Brief. Epicord umbilical cord allograft (MiMedx) for treating diabetic foot ulcers. <https://www.ecri.org>. Published February 6, 2020. Accessed January 12, 2023.
61. ECRI Institute. Product Brief. EpiFix amnion/chorion membrane allograft (MiMedx) for treating chronic wounds. <https://www.ecri.org>. Published September 10, 2018. Updated December 2, 2019. Accessed December 9, 2022.
62. ECRI Institute. Product Brief. FlexHD pliable acellular hydrated dermis (Musculoskeletal Transplant Foundation) for breast reconstructive surgery. <https://www.ecri.org>. Published October 30, 2015. Updated January 17, 2020. Accessed December 9, 2022.
63. ECRI Institute. Product Brief. Hyalomatrix tissue reconstruction matrix (Anika Therapeutics, Inc.) for treating burns. <https://www.ecri.org>. Published July 29, 2016. Updated June 10, 2018. Accessed December 9, 2022.

64. ECRI Institute. Product Brief. Integra flowable wound matrix (Integra LifeSciences Corp.) for treating diabetic foot ulcers. <https://www.ecri.org>. Published October 2, 2019. Accessed December 12, 2022.
65. ECRI Institute. Product Brief. NuCel human amniotic allograft (Organogenesis, Inc.) for use in orthopedic procedures. <https://www.ecri.org>. Published June 1, 2019. Updated February 1, 2020. Accessed December 12, 2022.
66. ECRI Institute. Product Brief. Omega3 wound matrix (Kerecis) for treating acute wounds. <https://www.ecri.org>. Published April 21, 2020. Accessed December 6, 2022.
67. ECRI Institute. Product Brief. PriMatrix dermal repair scaffold (Integra LifeSciences Corp.) for treating chronic wounds. <https://www.ecri.org>. Published July 25, 2016. Updated October 31, 2019. Accessed December 6, 2022.
68. ECRI Institute. Product Brief. Restrata resorbable wound matrix (Acera Surgical) for treating chronic wounds. <https://www.ecri.org>. Published July 1, 2019. Accessed December 6, 2022.
69. ECRI Institute. Product Brief. Strattice reconstructive tissue matrix (Allergan plc) for breast reconstruction. <https://www.ecri.org>. Published February 3, 2012. Updated November 25, 2019. Accessed December 9, 2022.
70. ECRI Institute. Product Brief. TheraSkin human skin allograft (Solsys Medical, LLC) for treating surgical and chronic wounds. <https://www.ecri.org>. Published October 5, 2018. Updated April 1, 2019. Accessed December 6, 2022.
71. ECRI Institute. Product Brief. XenMatrix surgical grafts (C.R. Bard, Inc.) for hernia repair. <https://www.ecri.org>. Published December 5, 2019. Accessed December 13, 2022.
72. ECRI Institute. Product Brief (ARCHIVED). Affinity human amniotic allograft (Nutech Medical) for use in chronic and surgical wounds. <https://www.ecri.org>. Published September 15, 2015. Accessed December 6, 2022.
73. ECRI Institute. Product Brief (ARCHIVED). AlloMax surgical graft (C.R. Bard, Inc./Davol, Inc.) for reconstructive surgery. <https://www.ecri.org>. Published October 9, 2015. Updated July 25, 2016. Accessed December 13, 2022.
74. ECRI Institute. Product Brief (ARCHIVED). AlloPatch HD acellular dermal matrix (Musculoskeletal Transplant Foundation) for repairing rotator cuff tears. <https://www.ecri.org>. Published October 23, 2017. Accessed December 9, 2022.
75. ECRI Institute. Product Brief (ARCHIVED). Biodesign dural graft (Cook Medical) for repairing dural tears. <https://www.ecri.org>. Published August 26, 2015. Accessed December 13, 2022.
76. ECRI Institute. Product Brief (ARCHIVED). Biodesign hernia graft (Cook Biotech, Inc.) for reconstructive surgery. <https://www.ecri.org>. Published July 20, 2016. Accessed December 13, 2022.

77. ECRI Institute. Product Brief (ARCHIVED). Biodesign nipple reconstruction cylinder (Cook Medical) for plastic surgery. <https://www.ecri.org>. Published April 5, 2018. Accessed December 13, 2022.
78. ECRI Institute. Product Brief (ARCHIVED). Biodesign otologic repair graft (Cook Medical) for tympanic reconstruction. <https://www.ecri.org>. Published January 22, 2018. Accessed December 9, 2022.
79. ECRI Institute. Product Brief (ARCHIVED). BioDFactor viable tissue matrix (Integra LifeSciences) for treating surgical and chronic wounds. <https://www.ecri.org>. Published September 24, 2018. Accessed December 12, 2022.
80. ECRI Institute. Product Brief (ARCHIVED). CopiOs pericardium membrane (Zimmer Dental, Inc.) for use during oral surgery. <https://www.ecri.org>. Published February 6, 2017. Accessed December 6, 2022.
81. ECRI Institute. Product Brief (ARCHIVED). Cytal wound matrix (ACell, Inc.) for treating acute and chronic wounds. <https://www.ecri.org>. Published October 23, 2017. Updated March 15, 2019. Accessed December 6, 2022.
82. ECRI Institute. Product Brief (ARCHIVED). Gentrax surgical matrix (ACell, Inc.) for reinforcing soft tissue. <https://www.ecri.org>. Published June 30, 2018. Accessed December 9, 2022.
83. ECRI Institute. Product Brief (ARCHIVED). GraftJacket Regenerative Tissue Matrix (Wright Medical Technology) to augment tendon and ligament repair. <https://www.ecri.org>. Published April 7, 2004. Updated February 12, 2018. Accessed December 13, 2022.
84. ECRI Institute. Product Brief (ARCHIVED). Helicoll (EnColl, Corp.) type-1 collagen-based sterile dressing for treating burns and wounds. <https://www.ecri.org>. Published August 1, 2014. Accessed December 6, 2022.
85. ECRI Institute. Product Brief (ARCHIVED). Integra flowable wound matrix (Integra LifeSciences Corp.) for treating deep soft-tissue or tunneling wounds. <https://www.ecri.org>. Published February 20, 2017. Accessed December 6, 2022.
86. ECRI Institute. Product Brief (ARCHIVED). Integra template and matrix wound skin substitutes (Integra LifeSciences Corp.) for treating chronic wounds. <https://www.ecri.org>. Published May 1, 2018. Accessed December 6, 2022.
87. ECRI Institute. Product Brief (ARCHIVED). MatriStem MicroMatrix (ACell, Inc.) for treating surgical and chronic wounds. <https://www.ecri.org>. Published August 28, 2018. Accessed December 6, 2022.
88. ECRI Institute. Product Brief (ARCHIVED). NuShield placental allograft (Nutech Medical) for use in chronic and surgical wounds. <https://www.ecri.org>. Published September 15, 2015. Accessed December 6, 2022.

89. ECRI Institute. Product Brief (ARCHIVED). Oasis wound matrix (Smith & Nephew, Inc.) for treating surgical and chronic wounds. <https://www.ecri.org>. Published April 7, 2004. Updated July 25, 2016. Accessed December 9, 2022.
90. ECRI Institute. Product Brief (ARCHIVED). Permacol surgical implant (Medtronic plc) for repairing hernias and abdominal wall defects. <https://www.ecri.org>. Published July 25, 2016. Accessed December 13, 2022.
91. ECRI Institute. Product Brief (ARCHIVED). Promogran Prisma Matrix (Acelyty L.P., Inc.) for promoting surgical wound healing. <https://www.ecri.org>. Published August 22, 2018. Accessed December 6, 2022.
92. ECRI Institute. Product Brief (ARCHIVED). Surgimend collagen matrix (Integra LifeSciences Corp.) for reconstructive surgery. <https://www.ecri.org>. Published July 5, 2016. Accessed December 13, 2022.
93. ECRI Institute. Product Brief (ARCHIVED). Surgisis Biodesign fistula plug (Cook Medical, Inc.) for repairing anal and rectovaginal fistulas. <https://www.ecri.org>. Published May 17, 2010. Updated June 8, 2012. Accessed December 13, 2022.
94. ECRI Institute. Product Brief (ARCHIVED). Veritas collagen matrix (Synovis Surgical Innovations) for surgically repairing soft-tissue deficiencies. <https://www.ecri.org>. Published March 6, 2013. Accessed December 9, 2022.
95. ECRI Institute. Product Brief (ARCHIVED). XCM biologic tissue matrix (Ethicon US, LLC/DePuy Synthes) for reconstructive surgery. <https://www.ecri.org>. Published November 4, 2015. Updated July 25, 2016. Accessed December 12, 2022.
96. ECRI Institute. Product Brief (ARCHIVED). XenMatrix Surgical Grafts (C.R. Bard, Inc./Davol, Inc.) for reconstructive surgery. <https://www.ecri.org>. Published October 30, 2015. Updated July 25, 2016. Accessed December 13, 2022.
97. Hayes, Inc. Evidence Analysis Research Brief. MicroMatrix (ACell Inc.) for treatment of wounds. <https://evidence.hayesinc.com>. Published March 25, 2022. Accessed December 13, 2022.
98. Hayes, Inc. Evidence Analysis Research Brief. Mirragen Advanced Wound Matrix (ETS Wound Care) for management of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published May 2, 2022. Accessed December 13, 2022.
99. Hayes, Inc. Evidence Analysis Research Brief. NuShield placental allograft for the management of diabetic foot ulcers. <https://evidence.hayesinc.com>. Published March 17, 2022. Accessed December 13, 2022.
100. Hayes, Inc. Evidence Analysis Research Brief (ARCHIVED). Amniotic allografts to promote postoperative healing of abdominopelvic wounds. <https://evidence.hayesinc.com>. Published June 11, 2020. Accessed December 13, 2022.

101. Hayes, Inc. Evidence Analysis Research Brief (ARCHIVED). Amniotic membrane allografts for vaginal indications. <https://evidence.hayesinc.com>. Published August 23, 2021. Accessed December 13, 2022.
102. Hayes, Inc. Evidence Analysis Research Brief (ARCHIVED). ArthroFLEX decellularized dermal allograft augmentation in arthroscopic superior capsule reconstruction. <https://evidence.hayesinc.com>. Published January 11, 2021. Accessed December 13, 2022.
103. Hayes, Inc. Evidence Analysis Research Brief (ARCHIVED). EpiCord dehydrated human umbilical cord (MiMedx) for treatment of chronic wounds. <https://evidence.hayesinc.com>. Published April 13, 2020. Accessed December 13, 2022.
104. Hayes, Inc. Evidence Analysis Research Brief (ARCHIVED). Two-stage Integra wound reconstruction following skin cancer surgery. <https://evidence.hayesinc.com>. Published August 25, 2020. Accessed December 13, 2022.
105. Hayes, Inc. Evolving Evidence Review. Kerecis Omega3 wound (Kerecis Limited) for the management of chronic lower extremity wounds. <https://evidence.hayesinc.com>. Published February 1, 2022. Accessed December 13, 2022.
106. Hayes, Inc. Evolving Evidence Review. PuraPly AM antimicrobial wound matrix (Organogenesis) for treatment of wounds. <https://evidence.hayesinc.com>. Published December 12, 2022. Accessed December 13, 2022.
107. Hayes, Inc. Health Technology Assessment. Acellular skin substitutes for chronic foot ulcers in adults with diabetes mellitus. <https://evidence.hayesinc.com>. Published May 6, 2020. Updated April 25, 2022. Accessed December 13, 2022.
108. Hayes, Inc. Health Technology Assessment. Amniotic allografts for tendon and ligament injuries. <https://evidence.hayesinc.com>. Published September 16, 2020. Updated September 9, 2022. Accessed December 13, 2022.
109. Hayes, Inc. Health Technology Assessment. Cellular skin substitutes for chronic foot ulcers in adults with diabetes mellitus. <https://evidence.hayesinc.com>. Published March 26, 2020. Updated March 9, 2022. Accessed December 13, 2022.
110. Hayes, Inc. Health Technology Assessment. Grafix cryopreserved placental membrane (Osiris Technologies Inc.) for treatment of chronic foot ulcers in patients with diabetes mellitus. <https://evidence.hayesinc.com>. Published September 3, 2019. Updated October 25, 2022. Accessed December 13, 2022.
111. Hayes, Inc. Health Technology Assessment. Processed nerve allografts with the Avance Nerve Graft (Axogen Corporation) for peripheral nerve discontinuities. <https://evidence.hayesinc.com>. Published March 2, 2020. Updated February 4, 2022. Accessed December 13, 2022.

112. Hayes, Inc. Health Technology Assessment. Skin substitutes for venous leg ulcers in adults. <https://evidence.hayesinc.com>. Published July 23, 2020. Updated August 16, 2022. Accessed December 13, 2022.
113. Hayes, Inc. Health Technology Brief (ARCHIVED). FlexHD acellular dermis (Musculoskeletal Transplant Foundation) for hernia repair. <https://evidence.hayesinc.com>. Published August 8, 2012. Updated June 30, 2014. Accessed December 13, 2022.
114. Hayes, Inc. Health Technology Brief (ARCHIVED). Oasis wound matrix (Cook Biotech Inc.) for lower extremity ulcers. <https://evidence.hayesinc.com>. Published December 31, 2012. Updated December 12, 2014. Accessed December 13, 2022.
115. Hayes, Inc. Health Technology Brief (ARCHIVED). SurgiMend (Integra Life Sciences) for postmastectomy breast reconstruction. <https://evidence.hayesinc.com>. Published April 27, 2017. Updated May 2, 2019. Accessed December 13, 2022.
116. Hayes, Inc. Health Technology Brief (ARCHIVED). Surgisis AFP anal fistula plug (a.k.a. SIS Fistula Plug) (Cook Biotech Inc.) for repair of anal fistulas. <https://evidence.hayesinc.com>. Published April 7, 2008. Updated April 9, 2010. Accessed December 13, 2022.
117. Hayes, Inc. Medical Technology Directory. Comparative effectiveness review of biologic mesh for hernia repair: a review of reviews. <https://evidence.hayesinc.com>. Published March 16, 2018. Updated March 1, 2022. Accessed December 13, 2022.
118. Hayes, Inc. Medical Technology Directory. Comparative effectiveness review of human acellular dermal matrix for breast reconstruction. <https://evidence.hayesinc.com>. Published January 28, 2019. Updated February 28, 2022. Accessed December 13, 2022.
119. Hayes, Inc. Medical Technology Directory (ARCHIVED). Biological tissue-engineered skin substitutes for wound healing. <https://evidence.hayesinc.com>. Published January 28, 2010. Updated February 11, 2014. Accessed December 13, 2022.
120. Hayes, Inc. Medical Technology Directory (ARCHIVED). Biosynthetic tissue-engineered skin substitutes for wound healing. <https://evidence.hayesinc.com>. Published January 14, 2010. Updated February 14, 2014. Accessed December 13, 2022.
121. Hayes, Inc. Medical Technology Directory (ARCHIVED). Synthetic tissue for dural repair. <https://evidence.hayesinc.com>. Published May 14, 2015. Updated June 11, 2019. Accessed December 13, 2022.
122. MCG Health. Skin substitute, tissue-engineered (human cellular), for diabetic foot ulcer and venous ulcer. 26th edition. <https://www.mcg.com>. Accessed August 2, 2022.

123. National Pressure Injury Advisory Panel (NPIAP). Clinical Practice Guideline. Prevention and treatment of pressure ulcers/injuries: quick reference guide. <https://www.npiap.com>. Published 2009. Updated 2019. Accessed December 14, 2022.
124. Society for Vascular Surgery (SVS). Clinical Practice Guidelines (ARCHIVED) of the Society for Vascular Surgery and the American Venous Forum. Management of venous leg ulcers. <https://www.jvascsurg.org>. Published August 2014. Accessed December 14, 2022.
125. UpToDate, Inc. Basic principles of wound management. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
126. UpToDate, Inc. Implant-based breast reconstruction and augmentation. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
127. UpToDate, Inc. Management of diabetic foot ulcers. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
128. UpToDate, Inc. Management of ventral hernias. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
129. UpToDate, Inc. Medical management of lower extremity chronic venous disease. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
130. UpToDate, Inc. Operative management of anorectal fistulas. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
131. UpToDate, Inc. Overview of surgical procedures used in the management of burn injuries. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
132. UpToDate, Inc. Overview of treatment of chronic wounds. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
133. UpToDate, Inc. Primary operative management of hand burns. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
134. UpToDate, Inc. Skin substitutes. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
135. UpToDate, Inc. Topical agents and dressings for local burn wound care. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.
136. UpToDate, Inc. Treatment of superficial burns requiring hospital admission. <https://www.uptodate.com>. Updated November 2022. Accessed December 13, 2022.

137. US Food & Drug Administration (FDA). 510(k) summary. Bilayer Matrix Wound Dressing. <https://www.fda.gov>. Published May 23, 2002. Accessed January 14, 2022.
138. US Food & Drug Administration (FDA). 510(k) summary. Biobrane. <https://www.fda.gov>. Published November 28, 1989. Accessed January 14, 2022.
139. US Food & Drug Administration (FDA). 510(k) summary. Integra Meshed Bilayer Wound Matrix. <https://www.fda.gov>. Published December 4, 2008. Accessed January 14, 2022.
140. US Food & Drug Administration (FDA). 510(k) summary. Oasis Wound Matrix. <https://www.fda.gov>. Published July 19, 2006. Accessed January 14, 2022.
141. US Food & Drug Administration (FDA). Premarket approval (PMA) summary. Transcyte. <https://www.fda.gov>. Published March 18, 1997. Accessed January 14, 2022.
142. US Food & Drug Administration (FDA). Safety Communication. Acellular dermal matrix (ADM) products used in implant-based breast reconstruction differ in complication rates. <https://www.fda.gov>. Published March 31, 2021. Accessed April 8, 2021.
143. US Food & Drug Administration (FDA). Summary of safety and effectiveness data: Apligraf (Graftskin). <https://www.fda.gov>. Published May 22, 1998. Accessed January 14, 2022.
144. US Food & Drug Administration (FDA). Summary of safety and effectiveness data: Dermagraft. <https://www.fda.gov>. Published September 28, 2001. Accessed January 14, 2022.
145. US Food & Drug Administration (FDA). Summary of safety and effectiveness data: Integra Dermal Regeneration Template and Integra Omnigraft Dermal Regeneration Matrix. <https://www.fda.gov>. Published January 7, 2016. Accessed January 14, 2022.

Appendix

Appendix A

Standard wound therapy based on the specific type of wound includes:

- Appropriate offloading; **AND**
- Assessment of an individual's vascular status and correction of any amenable vascular problems for arterial and/or venous ulcers; **AND**
- Comprehensive patient assessment (history, exam, Ankle-Brachial Index [ABI]) and diagnostic tests as indicated) and implemented treatment plan; **AND**
- Compression garments/dressings have been consistently applied for venous ulcers; **AND**
- Frequent repositioning of an individual with pressure injuries (usually every 2 hours); **AND**
- Improvement of glucose control with documented (within the past 90 days) glycosylated hemoglobin level (HbA1c) less than 9.0% or blood glucose records demonstrating efforts to sustain blood sugar less than 200 mg/dL; **AND**
- Individual with venous leg ulcer (VLU) - assessment of clinical history (prior ulcers, thrombosis risks), physical exam (edema, skin changes), ABI, diagnostic testing to verify superficial or deep venous reflux, perforator incompetence, and chronic (or acute) venous thrombosis; **AND**
- Maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings (eg, alginate, films, foams, hydrocolloid, hydrogels that provide a moist wound environment); **AND**
- Necessary treatment to resolve any infection that may be present (eg, antibiotics, debridement of devitalized tissue, surgical management of osteomyelitis); **AND**
- Optimization of nutritional status with documented prealbumin level greater than 20 mg/dL or albumin level greater than 3.4 g/dL

Change Summary

- 01/01/2024 New Policy.